CLINICAL STUDY PROTOCOL
Study Title: A Phase 2, Multicenter, Open- Label Study  to Evaluate the Efficacy  
and Safet y of Sofosbuvir/Velpatasvir Fixed -Dose Combination and 
Ribavirin for 12 Weeks in Subjects with Chronic HCV I nfection and 
Child -Pugh -Turcotte Class C Cirrhosis
Sponsor: [COMPANY_009] Sciences, Inc.
[ADDRESS_238065] 
Foster City , CA [ZIP_CODE], [LOCATION_003]
IND Number:
EudraCT Number :
Clinical Trials.gov 
Identifier :[PHONE_4297]-003066-10
Not Available
Indication: Hepatitis C Virus I nfection 
Protocol ID: GS-US-342-4022
[COMPANY_009] Study Director: Name:
[CONTACT_10880]:
Fax:
Email:
Protocol Version/Date: Original: [ADDRESS_238066] 2016
Amendment 1: [ADDRESS_238067] or Independent Ethics Committee. The information is only  to be used b y you in 
connection with authorized clinical studies of the investigational drug described in the protocol. 
You will not disclose any of the information to others without written authorization from 
[COMPANY_009] Sciences, Inc., except to the extent necessary  to obtain informed consent from those 
persons to whom the drug may  be administered.
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
SOF/VEL
Protocol GS -US-342-[ADDRESS_238068] OF IN-TEXT TABLES ........................................................................................................................................ 5
PROTOCOL SYNOPSIS .............................................................................................................................................. 6
GLOSSARY OF ABBREVIA TIONS AND DEFINITION OF TERMS .................................................................... 11
1. INTRODUCTION .............................................................................................................................................. 14
1.1. Background ............................................................................................................................................ 14
1.2. Sofosbuvir/Velpatasvir Fixed -Dose Combination ................................................................................. 15
1.2.1. General Information ............................................................................................................. 15
1.3. Ribavirin (RBV) ..................................................................................................................................... 15
1.4. Rationa le for This Study ........................................................................................................................ 15
1.5. Rationale for Dose Selection of SOF/VEL ............................................................................................ 16
1.6. Rationale for Dose Selection of Ribavirin .............................................................................................. 16
1.7. Risk/Benefit Assessment for the S tudy .................................................................................................. 17
1.8. Com pliance ............................................................................................................................................ 17
2. OBJECTIVES ..................................................................................................................................................... 18
3. STUDY DESIGN ................................................................................................................................................ 19
3.1. Study Design .......................................................................................................................................... 19
3.2. Visit Schedule ...............................................................
......................................................................... 19
3.3. Duration of Treatment ............................................................................................................................ 19
3.4. Treatment Discontinuation ..................................................................................................................... 19
3.4.1. Treatment Discontinuation Criteria ...................................................................................... 19
3.4.2. Toxicity -Based Stoppi[INVESTIGATOR_2121] ......................................................................................... 20
3.5. Virologic Response- Based Stoppi[INVESTIGATOR_2121] ......................................................................................... 20
3.6. Substudies and Registry Studies ............................................................................................................. 21
3.6.1.  
............................................................................................................................... 21
3.6.2. Sequence Registry Study (GS -US-248-0123) ...................................................................... 21
3.6.3. Cirrhosis SVR Registry Study (GS-US-337-1431) .............................................................. [ADDRESS_238069] Selection ............................................................................................ 22
4.2. Inclusion Criteria ................................................................................................
.................................... 22
4.3. Exclusion Criteria ................................................................................................................................... 23
5. INVESTIGATIONAL MEDI CINAL PRODUCTS ........................................................................................... 26
5.1. Randomization, Blinding and Treatment Codes .................................................................................... 26
5.2. Description and Handling of SOF/VEL FDC ........................................................................................ 26
5.2.1. Form ulation .......................................................................................................................... 26
5.2.2. Packaging and Labeling ....................................................................................................... 26
5.2.3. Storage and Handling ........................................................................................................... 26
5.3. Description and Handling of Ribavirin (RBV) ...................................................................................... 27
5.3.1. Form ulation .......................................................................................................................... 27
5.3.2. Packaging and Labeling ....................................................................................................... 27
5.3.3. Storage and Handling ........................................................................................................... 27
5.4. Dosage and Administration of SOF/VEL andRBV ............................................................................... 27
5.5. Prior and Concomitant Medications ...............................................................
........................................ 28
5.6. Accountability for SOF/VEL+RBV ....................................................................................................... 31
[COMPANY_003]
SOF/VEL
Protocol GS -US-342-[ADDRESS_238070] Enrollment and Treatment Assignment ..................................................................................... 32
6.1.1. Screening Visit (Day -28 to Day 0) ...................................................................................... 32
6.2. Treatment Phase: Treatment Assessments ............................................................................................. 34
6.2.1. Day 1 Assessments ............................................................................................................... 34
6.2.2. Study Drug Administration .................................................................................................. 35
6.2.3. Week 2 (3 days) ................................................................................................................ 35
6.2.4. Weeks 4 and 8 ( 3 days) ..................................................................................................... 36
6.2.5. Week 12 ( 3 days) or Early Termination ............................................................................ 37
6.3. Posttreatment Assessments .................................................................................................................... 38
6.3.1. 4-Week Posttreatment Visit ( 5 days) ................................
................................................. 38
6.3.2. 12 & 24 Week Posttreatment Visit ( 5 days) ...................................................................... 38
6.4. Assessments for Premature Discontinuation from Study ....................................................................... 39
6.5. Procedures and Specifications ................................................................................................................ 39
6.5.1. Clinical Laboratory Analytes ............................................................................................... 39
6.5.2. Medical History .................................................................................................................... 40
6.5.3. Com plete Physical Examination ........................................................................................... 40
6.5.4. Height & Weight Measurement ............................................................................................ 40
6.5.5. Vital Signs ............................................................................................................................ 40
6.5.6. Body  Mass Index (BMI) ....................................................................................................... 41
6.5.7. MELD and CPT Score Calculations ..................................................................................... 41
6.5.8. Creatinine Clearance ............................................................................................................ 42
6.5.9. 12-Lead ECG ........................................................................................................................ 42
6.5.10. Viral Sequencing (Archive) .................................................................................................. 42
6.5.11. Single Pharmacokinetic (PK) Sample ...............................................................
................... 42
6.5.12. HBV DNA Sample ............................................................................................................... 42
6.5.13. IL28B Testing ...................................................................................................................... 43
6.5.14. Archive Plasma Sample ...............................................................
......................................... 43
6.5.15. .................................................................................................. 43
6.5.16. Pregnancy Testing ...............................................................
................................................. 43
6.5.17. Health Related Quality of Life Survey ................................................................................. 43
7. ADVERSE EVENTS AND TOXICITY MANAGEMENT ............................................................................... 44
7.1. Definitions of Adverse Events, Adverse Reactions, and Serious Adverse Events ................................. 44
7.1.1. Adverse Events ..................................................................................................................... 44
7.1.2. Serious Adverse Events ........................................................................................................ 44
7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events ......................................................................... 45
7.2. Assessment of Adverse Events and Serious Adverse Events ................................................................. 45
7.2.1. Assessment of Causality for Study Drugs and Procedures ................................................... 45
7.2.2. Assessment of Severity ........................................................................................................ 46
7.3. Investigator Requirements and Instr uctions for Reporting Adverse Events and Serious 
Adverse Events to [COMPANY_009] ....................................................................................................................... 46
7.3.1. Adverse Events ...............................................................
...................................................... 46
7.3.2. Serious Adverse Events ........................................................................................................ 46
7.4. [COMPANY_009] Reporting Requirements ............................................................................................................. 48
7.5. Toxicity Management ............................................................................................................................ 48
7.5.1. Dose Adjustments ................................................................................................................ 48
7.5.2. Management of Rejection ...............................................................
..................................... 48
7.6. Special Situat ions Reports ...................................................................................................................... 49
7.6.1. Definitions of Special Situations .......................................................................................... 49
7.6.2. Instructions for Reporting Special Situations ....................................................................... 50
[COMPANY_003]
SOF/VEL
Protocol GS -US-342-[ADDRESS_238071] (IRB)/Independent Ethics Committee (IEC) 
Revie w and Approval ...............................................................
............................................ [ADDRESS_238072] Accountability and Return ............................................. 61
9.1.8. Inspections ............................................................................................................................ 61
9.1.9. Protocol Compliance ............................................................................................................ 62
9.2. Sponsor Responsibilities ........................................................................................................................ 62
9.2.1. Protocol Modifications ................................
......................................................................... 62
9.2.2. Study Report and Publications ............................................................................................. 62
9.3. Joint Investigator/Sponsor Responsibilities ........................................................................................... 62
9.3.1. Payment Reporting ............................................................................................................... 62
9.3.2. Access to Information for Monitoring .................................................................................. 63
9.3.3. Access to Information for Auditing or Inspections .............................................................. 63
9.3.4. Study Discontinuation .......................................................................................................... 63
10. REFERENCES ................................................................................................................................................... 64
11. APPENDICES .................................................................................................................................................... 66
Appendix 1. Investigator Signature [CONTACT_3490] .................................................................................................... 67
Appendix 2. Study Procedures Table .......................................................................................................... 68
Appendix 3. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities ............... 70
Appendix 4. Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements ................................................................................................... 92
SOF/VEL
Protocol GS -US-342-[ADDRESS_238073] OF IN -TEXT TABLES
Table 5-1. Suggested Dose Administration of RBV ................................................................................ 28
Table 5-2. Disallowed and Concomitant Medications to be Used w ith Caution ..................................... 29
Table 6-1. Child- Pugh -Turcotte Classification of the severity of cirrhosis ............................................. 41
SOF/VEL
Protocol GS -US-342-[ADDRESS_238074] 
Foster City, CA [ZIP_CODE], [LOCATION_003]
Study Title: A Phase 2, Multicenter, Open -Label Study  to Evaluate the Efficacy  
and Safet y of Sofosbuvir/Velpatasvir Fixed -Dose Combination and 
Ribavirin for 12 Weeks in Subjects with Chronic HCV Infection and 
Child -Pugh -Turcotte C lass C Cirrhosis
IND Number:
EudraCT Number:
Clinical Trials.gov 
Identifier:118605 
2016-003066-10
Not Available
Study Centers 
Planned:Approximately  20 centers in [LOCATION_002] and Europe
Objectives: The primary  objectives of this study  are:
To evaluate the efficacy  of treatment with sofosbuvir 
(SOF)/velpatasvir (VEL) fixed -dose combination (FDC) with 
ribavirin (RBV) for 12 weeks in subjects with chronic 
hepatitis C 
virus ( HCV )infection and C hild-Pugh -Turcotte (C PT)class C 
cirrhosis as measured b y the proportion of subjects with sustained 
viral response 12 weeks after cessation of treatment (SVR12)
To evaluate the safet y and tolerability  of the treatment regimen 
The secondary  objectives of this study  are:
To de termine the proportion of subjects who attain SVR at 4 and 
24 weeks after cessation of the study  treatment regimen (SVR4 
and SVR24)
T
o evaluate the proportion of subjects with virologic failure
To evaluate therapeutic efficacy  as measured b y the change of
CPT score and Model for End Stage Liver Disease ( MELD )score
To evaluate the kinetics of circulating HCV RNA during 
treatment and after cessation treatment
To evaluate the emergence of viral resistance to SOF and VEL 
during treatment and after cessation of treatment
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 7 22 November 2016The exploratory  objective sof this study  are:
 
 
Study Design: Approximately  50 subjects with chronic HCV infection and CPT 
Class C cirrhosis will be enrolled and treated with SOF/VEL 
Fixed-Dose Combination (FDC )tablet with RBV for 12 weeks. 
Substudies and 
Registry  Studies:  
Sequence Registry  Study (GS-US-248-0123)
Subjects who do not achieve SVR will be eligible for enrollment in an 
Observational Sequence Registry  Study . The purpose of the Sequence
Registry  Study  will be to monitor the persistence of HCV resistant 
mutations. The Sequence Registry  Study  is described in a separate 
protocol .
Cirrhosis SVR Registry  Study (GS-US-337-1431)
Cirrhotic s ubjects who achieve SVR will be eligible for enrollment in 
the Cirrhosis SVR Registry  Study . The purpose of the Cirrhosis SVR
Registry  Study  will be to evaluate durability  of SVR and the 
progression or regression of liver disease for up to 5 y ears 
posttreatment .  The Cirrhosis SVR Registry  Study  is described in a 
separate protocol.
Number of Subjects 
Planned:Approximately  50 subjects
Target Population: Adults with chronic HCV infection and CPT C cirrhosis.
Duration of 
Treatment:12 weeks
Diagnosis and Main 
Eligibility  Criteria:Chronic HCV infected, male and non -pregnant/non -lactating female 
subjects aged 18 years or older with CPT C cirrhosis. 
See the Sections 4.2and 4.3for full eligibility  criteria.
[COMPANY_003]
[COMPANY_003]
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 8 22 November 2016Study  Procedures/
Frequency :Screening assessments will be completed within 28 day s of the Day 1 
visit. The screening window can be extended to 42 days for subjects 
in extenuating circumstances with Sponsor approval.
All subjects will complete the following stud y visits: Screening, 
Day 1, on- treatment visits at the end of Weeks 2, 4, 8, and 12, and 
posttreatment visits at Week 4 and 12, after completion of treatment.  
Subjects who achieve SVR12 will complete the posttreatment 
Week 24 visit. 
Screening assessments will include obtaining informed consent, 
physical examination, medical history , height, weight, vital signs, 
12-lead electrocardiogram (ECG),  adverse events (AEs) related to 
screening procedures, concomitant medications, safet y laboratory 
tests (including hematology , chemistry , and coagulation), calculation 
of CPT and MEL D scores, HC V RNA, HCV genoty pi[INVESTIGATOR_007], serology  
(HIV, HCV, HBV), hemoglobin A1c (HbA1c), screening for 
hepatocellular carcinoma (HCC), serum β -hCG (females of child 
bearing potential onl y),  IL28B genot ypi[INVESTIGATOR_007], urinalysis and urine drug 
screen.
On-treatment assessments inc lude AEs, concomitant medications, 
calculation of CPT and MEL D scores, study  drug pi[INVESTIGATOR_692], phy sical 
examination, weight, vital signs, safet y laboratory  tests, HCV RNA, 
HRQoL  survey s, urinal ysis and urine pregnancy tests (females of 
child bearing potential only ).
Single 12
-lead ECGs will be collected at Screening and Day 1 (prior 
to study  drug administration). At the time of ECG collection, printed 
copi[INVESTIGATOR_014] (paper) will be reviewed b y qualified stud y staff (as 
determined b y the Investigator).
Posttreatment assessments include AEs, concomitant medications, 
vital signs, weight, safety laboratory  tests, calculation of CPT and 
MEL D scores, pregnancy  prevention counseling, phy sical 
examination, HCV RNA, HRQoL  survey s, and urine pregnancy  tests 
(females of child b earing potential only ).
HRQoL  survey s (SF-36, CL DQ-
HCV, FACIT- F, and WPAI ) will be 
conducted at Day  1, on- treatment Week 12, Earl y Termination (ET )
(if applicable), and posttreatment Weeks 12 (if applicable).
Samples for viral RNA sequencing/phenot ypi[INVESTIGATOR_199588] 1 and every  visit thereafter. Samples will be collected during 
on-treatment visits for pharmacokinetic (PK) analy sis of study  drugs. 
For subjects who are Hepatitis B core antibody  positive (HBcAb+)
, 
HBV DNA will be measured at Day  1, on- treatment Weeks 4, 8, 12, 
and posttreatment Weeks 4, 12, and 24.
SOF/VEL
Protocol GS -US-342-[ADDRESS_238075], Dose, 
and Mode of 
Administration:SOF/VEL FDC is manufactured as a 400mg/100 mgFDC tablet for 
oral administration. Subjects will take 1 tablet daily  with or without 
food. 
RBV is manufactured as a 200 mg tablet for oral administration. 
Subjects will take a starting dose of 600mg RBV with food in a 
divided daily  dose . 
If the starting dose is well-tolerated, RBV can be titrated up to a 
maximum of 1000 -1200 mg dail y (1000 mg for subjects 
weighing <75 kg and 1200 mg for subjects weighing 75kg) 
divided twice dail y. If the starting dose is not well tolerated, the dose 
should be reduced as necessary .
Reference Therapy, 
Dose, and Mode of 
Administration:None
Criteria for 
Evaluation:
Safety : AEs and laboratory  tests will be collected throughout the study .
Efficacy : Efficacy  will be evaluated using scheduled assessments of HCV RNA 
performed using COBAS®AmpliPrep®/COBAS®TaqMan®HCV 
Quantitative Test, v2.0 .
Efficacy  will also be assessed based on MELD and CPT scores on-
treatment and posttreatment .
Pharmacokinetics: A single PK blood sample will be collected at each on -treatment visit 
for all subjects. 
The PK of SOF (and metabolites), VEL and RBV may  be assessed.
[COMPANY_003]
[COMPANY_003]
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 10 22 November 2016Statistical Methods: The primary  efficacy  endpoint for the study is SVR12 in all enrolled 
and treated subjects. In the primary  efficacy  analy sis, point estimate 
and 95% confidence interval (using the Clopper -Pearson method) of 
SVR12 will be computed.
Secondary  endpoints include SVR4 and SVR24; proportion of 
subjects who have HCV RNA < LLOQ b y visit while on study  
treatment; absolute and change from Day  1 in HCV RNA; virologic 
failure; and change from Day 1 in MELD and CPT scores.
With a sample size of approximately  50 subjects, a 2- sided 95% exact 
confidence interval of the SVR12 rate will extend at most 29% in 
length.
This study  will be conducted in accordance with the guidelines of Good Clinical Practice (GCP) 
including archiving of essential documents.
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 11 22 November 2016GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS
C degrees Celsius
F degrees Fahrenheit
ACR acute cellular rejection
AE adverse event
AFP alpha -fetoprotein
ALT alanine aminotransferase (also SGPT)
ANC absolute neutrophil count
APTT activated partial thromboplastin time
AST aspartate aminotransferase (also SGOT)
BMI body mass index
CK creatine kinase
CT computed tomography
ClCr creatinine clearance
CRF case report form(s)
CRO contract (or clinical) research organization 
CPT Child- Pugh -Turcotte 
CSA colony stimulating agents
DAA direct acting antiviral
DCV daclatasvir
dL deciliter
DNA deoxyribonucleic acid
DSPH Drug Safety and Public Health
ECG electrocardiogram
eCRF electronic case report form(s)
ESA erythropoiesis stimulating agent
ET early termination
EU European Union
FAS Full Analysis Set
FDA ([LOCATION_002]) Food and Drug Administration
FDC Fixed -Dose Com bination
FEV 1 forced expi[INVESTIGATOR_199589] (Guidelines)
GM- CSF granulocyte -macrophage colony  stimulating factor
GGT gamma glutamyl transferase
GSI [COMPANY_009] Sciences, Inc.
Hb hemoglobin
HbA1c hemoglobin A1c
HBcAb Hepatitis B core antibody
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 12 22 November 2016HBcAb+ Hepatitis B core antibody positive
HBsAb Hepatitis B surface antibody
HBsAg Hepatitis B surface antigen
HBsAg+ Hepatitis B surface antigen positive
HBV Hepatitis B virus
HCC hepatocellular carcinoma
HCV Hepatitis C virus
HDPE high-density polyethylene
HIV Human Immunodeficiency Virus
HLGT High -Level Group Term
HLT High -Level Term
HRQoL Health -Related Quality of Life
ICH International Conference on Harmonisation
IEC independent ethics committee
IL28B IL28B gene
INR international normalized ratio
IRB institutional review board
IUD intrauterine device
IWRS interactive web response system
kg kilogram
L liter
LDV ledipasvir, GS -[ADDRESS_238076] lower limit of the normal range
LLOQ lower limit of quantification
LLT Lower-Level Term 
MedDRA Medical Dictionary for Regulatory Activities
MELD Model for End Stage Liver Disease
mg milligram
mL milliliter
min minute
mmHg millimeters mercury
MRI magnetic resonance imaging
NS (3/4A/5A/5B) non-structural protein
PBMC peripheral blood mononuclear cell(s)
P-gp P-glycoprotein
PK pharmacokinetic
PPI [INVESTIGATOR_199590]/VEL
Protocol GS -US-342-[ADDRESS_238077] upper limit of the normal range
US [LOCATION_002]
US PI [INVESTIGATOR_199591], GS -5816
WBC white blood cell 
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 14 22 November [ZIP_CODE]. INTRODUCTION
1.1. Background
Hepatitis C virus infection is a global health challenge with the estimated number of persons 
infected ranging from 80 to 150 million worldwide {Gower et al 2014 , World Health 
Organization (WHO) 2014 }. Hepatitis C virus has significant genetic (RNA sequence) 
variability  and is classified on this basis into at least [ADDRESS_238078] Asia, respectively . 
The disease burden of HCV infection is due to progression of chronic liver disease, which can 
lead to cirrhosis, liver failure, hepat ocellular carcinoma, and death. Globally , 27% of all patients 
with cirrhosis and 25% of those who develop hepatocellular carcinoma are attributable to HCV 
infection {Perz et al 2006 }.In addition to having a higher incidence of hepatocellular carcinoma, 
patients with chronic HCV infection have a higher incidence and mortality  of many  types of 
nonliver cancers including pancreatic, rectal, kidney , non-Hodgkin l ymphoma and lung cancers, 
compared with the general population {Allison et al 2015 }. Curing HCV infection is associated 
with numerou s health benefits including more than 70% reduction in the risk of hepatocellular 
carcinoma and a 90% reduction in the risk of liver- related mortality  and liver transplantation 
{Morgan et al [ADDRESS_238079] et al 2002 , van der Meer et al 2012 , Veldt et al 2007}.
Recently , there has been a transformation in the treatment of HCV in fection with the 
development of DAAs targeting viral proteins essential to viral replication. DAA based treatment 
regimens are generall y well tolerated and result in high rates of sustained virologic response at 
12weeks following completion of all treatme nt (SVR12) across most patient populations 
{[COMPANY_009] Sciences Inc 2013 , [COMPANY_009] Sciences Inc 2016a , [COMPANY_009] Sciences Inc 2016b}. 
Sofosbuvir -based regimens (Sovaldi®and Harvoni®) are the most widel y prescribed treatments 
for HCV infection due to the efficacy , tolerability, and simplicity  of the dosing regimens. In 
addition, sofosbuvir -based regimens offer the advantages of having relatively  few drug -drug 
interactions, strong concordance between clinical trial and “real world” dat a, and absence of a 
requirement for baseline NS5A poly morphism testing {Ioannou et al 2016
}The recent approvals 
in the US and EU of Epclusa®, a fixed dose combination of sofosbuvir and velpatasvir is an 
important advance in HCV drug development as Epclusa®is highly  efficacious across all HCV 
genot ypes whereas previously  approved regimens were HCV genot ype specifi c {Arias et al 
2016 , [COMPANY_009] Sciences Inc 2013 , [COMPANY_009] Sciences Inc 2016a , [COMPANY_009] Sciences I nternational Ltd 
2016, Ioannou et al 2016 }. 
Despi[INVESTIGATOR_199592] t reatments for HCV infection, many  
challenges remain. These include the evaluation of DAA based regimens in patient populations 
not evaluated in registration clinical studies, such as patients with advanced hepatic disease, or 
advanced renal disease and ped iatric populations. In addition, the treatment of populations with 
high HCV prevalence such as the incarcerated or injection drug users will require the 
SOF/VEL
Protocol GS -US-342-[ADDRESS_238080] 
prevale nce of HCV infection occurs in low and middle income countries, the development of 
treatment algorithms that can be implemented in resource limited settings will be necessary  to 
decrease the global prevalence and burden of HCV .
1.2. Sofosbuvir/Velpatasvir Fixed -Dose Combination
Sofosbuvir (SOF) is a nucleotide analog HCV NS5B pol ymerase inhibitor. Velpatasvir (VEL) is 
a pangenot ypic HCV NS5A inhibitor. SOF/VEL  (Epclusa®) is a co- formulation of SOF 400 mg 
and VEL 100 mg that is approved in the US, EU and other re gions for the treatment of HCV 
infection in adults.
1.2.1. General Information
Please refer to the Investigator’s Brochure (IB) for additional information on SOF/VEL, and the 
individual components, including:
In-Vitro Anti -Hepatitis C Virus Activity
Nonclinical P harmacokinetics and In Vitro Metabolism
Nonclinical Pharmacology and Toxicology
Clinical Experience
1.3. Ribavirin (RBV)
Ribavirin is a guanosine analogue that inhibits the in vitro replication of a wide range of 
RNA and DNA viruses { [COMPANY_002] Laboratories Inc. 2010 , [COMPANY_002] Products L imited 2010 }. 
Ribavirin monotherapy  has little or no effect on the replication of HCV in vivo but can result in
normalization of serum AL T activity  and improvement in liver histology . 
Ribavirin is a known terat ogen (FDA category  X). Furthermore, RBV is known to accumulate 
intracellularl y where it is cleared slowly, and is also excreted in semen. Therefore, extreme care 
must be taken to avoid pregnancy  during RBV therapy  and for up to 7 months following 
completio n of treatment, and in the case of males, impregnating a female while on RBV and up 
to7 months following completion of therap y.
A comprehensive review of RBV is contained in the US PI  [INVESTIGATOR_2808].
1.4. Rationale for This Study
The GS -US-342-4022 study  is a Phase 2 multicenter, open- label study  evaluating 
SOF/VEL +RBV for 12 weeks in subjects with HCV infection and Child -Pugh -Turcotte (CPT) 
class C (CPT C) cirrhosis. Approximately  50subjects will be enrolled.
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 16 22 November 2016SOF/VEL with RBV for 12 weeks is approved in the US and EU (as Epclusa®) for the treatment 
of HCV infection in patients with decompensated cirrhosis based on the results of the ASTRAL -
4 study {Curry  et al 2015}. However, of the 87 HCV infected subjects treated with SOF/VEL 
and RBV for 12 weeks in the ASTRAL -4 study , 77 (89%) had CPT B cirrhosis and only 4(5%) 
had CPT C cirrhosis at baseline. The regimen was efficacious with all 4 subjects with CPT C 
cirrhosis achieving SVR12. However 3 of 4 subjects with CPT C cirrhosis required dose 
reduction of RBV suggesting that weight
-based dosing of RBV may  not be a ppropriate for 
subjects with CPT C cirrhosis. An additional limitation of the ASTRAL -4 study  was that 
subjects who had received a liver transplant were not eligible .
Given the small number of subjects with CPT C cirrhosis evaluated with SOF/VEL+RBV in the 
ASTRAL -4 study , this study  will more comprehensively  evaluate the safety  and efficacy  of 
SOF/VEL+RBV in subjects with CPT C cirrhosis including patients who have received a liver 
transplant. 
1.5. Rationale for Dose Selection of SOF/VEL
Subjects in this study  will be administered SOF/VEL , a co -formulation of SOF 400 mg and VEL 
100 mg that is approved in the US, EU and other regions as Epclusa®for the treatment of HCV 
infection in adults. 
In the Phase 3 ASTRAL 1 -3 studies, treatment of HCV infected subjects without cirrhosis or 
with compensated cirrhosis for 12 weeks with SOF/VEL was well tolerated and resulted in high 
SVR12 rates. In the ASTRAL -4 study , treatment of HCV infected subjects with decompensated 
Child Pugh Turcotte class B cirrhosis with SOF/VEL  and ribavirin for [ADDRESS_238081] ed subjects, no dose adjustment of SOF/VEL 
is recommended in patients with CPT C cirrhosis. Refer to the SOF/VEL Investigator’s Brochure 
for additional information.
1.6. Rationale for Dose Selection of Ribavirin
Data from the ASTRAL -4 and SOLAR studies support a starting dose of RBV 600 mg in 
combination with SOF/VEL   for  subjects with CPT C cirrhosis in this study.
The ASTRAL -4 study  evaluated the safet y and efficacy of SOF/VEL with and without weight 
based RBV (1000- 1200 mg) for 12 weeks and SOF/VEL for 24 we eks in patients with 
decompensated cirrhosis. Of 87 subjects treated with SOF/VEL
 and RBV for 12 weeks, 
77(89%) had CPT B cirrhosis and 4 (5%) had CPT C cirrhosis at baseline. RBV dose reduction 
was required b y approximately one third of subjects with CPT B cirrhosis compared with 3 of 
4subjects with CPT C cirrhosis suggesting that weight based (1000 -1200 mg) RBV dosing was 
less tolerated in patients with CPT C cirrhosis compared with patients with CPT B cirrhosis.
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 17 22 November 2016The SOLAR -1 and SOLAR - 2 studies evaluat ed ledipasvir (LDV) /SOF and RBV 600mg for 
12or 24 weeks in pre - and posttransplant patients including patients with decompensated 
cirrhosis {Charlton et al 2015, Manns et al 2016 }. In these studies, treatment of subjects with 
CPT C cirrhosis with LDV/SOF and RBV 600mg for 12 or 24 weeks was well tolerated and 
resulted in high SVR12 rates. Based on the SOLAR data, the US PI  [INVESTIGATOR_199593] a 600 mg starting dose of RBV in HCV infected patients with decompensated 
cirrhosis {[COMPANY_009] Sciences I nc 2016b , [COMPANY_009] Sciences International Ltd. 2016 }.
1.7. Risk/Benefit Assessment for the Study
This study  will provide information of the safet y and efficacy of the combination of SOF /VEL 
plus RBV for 12 weeks in patients with CPT C decompensated cirrhosis.
The safet y profile of SOF/VEL has been established in 3126 subjects, including 1558 subjects in 
the Phase 3 studies, 802 in the Phase 2 studies, 499 in the Phase 1 studies, and 267 subjects with 
decompensated cirrhosis in the Phase 3Study  GS-US-342- 1137 (ASTRAL -4).No clinical safet y 
issues specificall y related to the combination of SOF/VEL have been identified to date. No 
clinical safet y issues specificall y related to the NS5A inhibitor class including daclatasvir (DCV) 
and LDV have been identified to date {
Afdhal et al 2014a , Afdhal et al 2014b , Kowdley  et al 
2014}. Overall , SOF/VEL plus RBV for [ADDRESS_238082] of the study , the sponsor will perform ongoing safet y review.
In summary , 
safety  and efficacy  of SOF/VEL plus RBV for 12 weeks has been evaluated in 
subjects with CPT B decompensa ted cirrhosis. This study  will evaluate this regimen in patients 
with more advanced liver disease.
1.8. Compliance
This study  will be conducted in compliance with this protocol, Good Clinical Practice (GCP), 
and all applicable regulatory  requirements.
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 18 22 November [ZIP_CODE]. OBJECTIVES
The primary  objectives of this study  are:
To evaluate the efficacy  of treatment with sofosbuvir (SOF)/velpatasvir (VEL) fixed -dose 
combination (FDC) with ribavirin (RBV) for 12 weeks  in subjects with chronic HCV 
infection and Child- Pugh -Turcott e (CPT) class C cirrhosis as measured b y the proportion of 
subjects with sustained viral response 12 weeks after cessation of treatment (SVR12)
To evaluate the safet y and tolerability  of the treatment regimen 
The secondary  objectives of this study  are:
To determine the proportion of subjects who attain SVR at 4 and 24 weeks after cessation of 
the study  treatment regimen (SVR4 and SVR24) 
To evaluate the proportion of subjects with virologic failure
To evaluate therapeutic efficacy  as measured b y the change of CPT score and MEL D score
To evaluate the kinetics of circulating HCV RNA during treatment and after cessation 
treatment
To evaluate the emergence of viral resistance to SOF and VEL during treatment and after 
cessation of treatment
The exploratory  objective sof this study  are:
 
 
 
[COMPANY_003]
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 19 22 November [ZIP_CODE]. STUDY DESIGN
3.1. Study Design
This is a multicenter, open -label study  evaluating the efficacy and safet yof SOF/VEL and RBV 
for12 weeks in chronic HCV infected subjects with CPT C cirrho sis.
3.2. Visit Schedule
Screening assessments will be completed within 28 day s of the Day  1 visit.  The screening 
window can be extended to 42 day s for extenuating circumstance with Sponsor approval .
All subjects will complete the following stud y visits: Screening, Day  1, on- treatment visits at the 
end of Weeks 2, 4, 8, and 12, and posttreatment visits at Week 4 and12,after completion of 
treatment.  Subjects who achieve SVR12 will alsocomplete the posttreatment Week 24 visit.
3.3. Duration of Treatment
Approximately  50 subjects will be enrolled and treated with SOF/VEL tablet once dail y and 
600-1200 mg RBV in a divided daily  dose with food.
The total time to complete all study  visits is approximately  40 weeks ( 42 weeks for those 
requiring extension of the Screen ingperiod ):
28 day s (4 week) screening period ( or42 day sfor extenuating circumstance s)
12 week stud y treatment period
[ADDRESS_238083] discontinues study  dosing (for example, as a result of an adverse event [AE]), every  
attempt should be made to keep the subject in the study  and continue to perform the required 
study -related follow
-up procedures (see Section 6.4). If thi s is not possible or acceptable to the 
subject or investigator, the subject may  be withdrawn from the study .
There is no option for SOF/VEL dose reduction due to toxicity . If SOF/VEL  is withheld due to 
toxicity , the subject must discontinue treatment and c omplete an Early Termination ( ET)visit. 
Subjects that require discontinuation of only  RBV for RBV -related events should continue with 
SOF/VEL for the remainder of the treatment period and complete all scheduled study  visits. 
SOF/VEL
Protocol GS -US-342-[ADDRESS_238084] be discontinued in the following instances:
Unacceptable toxicity , as defined in Section 3.4.[ADDRESS_238085]
Virologic failure (as defined in Section 3.5)
Pregnancy  of female subject or female partner of male subject 
Significa nt protocol violation including non -compliance with study  assessments
Subject request to discontinue for an y reason; it is important to determine whether the 
withdrawal of consent is primarily  due to an AE, lack of efficacy , or other reason
Discontinuation of the study  at the request of [COMPANY_009], regulatory  agency , or an Institutional 
Review Board (I RB)/Independent Ethics Committee (IEC)
3.4.2. Toxicity- Based Stoppi[INVESTIGATOR_199594]/VEL :
Confirmed t otal bilirubin > 3x Day  1 or nadir and AL T and/or AST > 3x Day  1 
or nadir
Elevation of alanine aminotransferase (ALT) and/or aspartate aminotransferase 
(AST) > 10x Day 1 or nadir, confirmed b y immediate repeat testing
Elevati on of ALT >15x ULN , confirmed by  [CONTACT_199607]
Any Grade 3 or greater rash associated with constitutional sy mptoms
Any non
-laboratory  Grade 4 event assessed as related to administration of SOF/VEL, study  
drugs should be discontinued immediately
3.5. Virologic Response- Based Stoppi[INVESTIGATOR_199595] -treatment virologic response- based treatment stoppi[INVESTIGATOR_199596]:
Confirmed HCV RNA ≥LLOQ after 2 consecutive HCV RNA <LLOQ
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 21 22 November 2016Confirmed >1 log 10  increase from on-treatment nadir 
HCV RNA ≥LLOQ through 8 weeks of treatment
3.6. Substudies and Registry Studies
 
 
 
 
 
3.6.2. Sequence Registry S tudy (GS-US-248-0123)
Subjects who do not achieve SVR will be eligible for enrollment in an observational Sequence 
Registry Study . The purpose of the Sequence Registry  Study  will be to monitor the persistence of 
HCV resistant mutations. The Sequence Registry  Study  is described in a separate protocol.
3.6.3. Cirrhosis SVR Registry Study (GS-US-337-1431)
Cirrhotic subjects who achieve SVR will be eligible for enrollment in the Cirrhosis SVR 
Registry  Study . The purpose of the Cirrhosis SVR Registry  Study  will be to evaluate durability  
of SVR and the progression or regression of liver disease for up to 5 years posttreatment. The 
Cirrhosis SVR Registry  Study  is described in a separate protocol.
[COMPANY_003]
SOF/VEL
Protocol GS -US-342-[ADDRESS_238086] Selection
Approximately  50 subjects will be enrolled in this study .  
In order to manage the total study  enrollment, [COMPANY_009] Sciences, Inc. at its sol e discretion, may  
suspend screening and/or discontinue the enrollment at any  site or study -wide at an y time 
(upon written notice to the site). Discontinuation of the enrollment phase may  result in the 
immediate ineligibility  of all subjects screened but no t yet enrolled, regardless of the progress or 
outcome of the screening assessments performed.
4.2. Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be eligible for participation in this 
study .
1)Willing and able to provide written informed consent
2)Males and females, age  ≥ 18 y ears old
3)A body  mass index (BM I) of ≥ 18 kg/m2
4)Chronic HCV infection ( ≥ 6 months) as documented by  [CONTACT_199608]
5)Quantifiable HCV RNA at S creening
6)Subjects may  be non-transplant ed or with recurrent HCV post- liver transplant. 
a.If listed for liver transplant, then the projected date of transplant must be ≥[ADDRESS_238087] be ≥ 6 months from date of transplant
7)CPT score of 10 to 12, inclusive, a sdetermined at Screening
8)Liver imaging within 6 months of Day  1 to exclude HCC
9)If treatment -experienced, the most recent HCV treatment must have been completed at least 
8 weeks prior to Screening
10)Females of childbearing potential (as de fined in Appendix 4) must have a negative serum 
pregnancy  test at Screening and a negative urine pregnancy  test on Day  1 prior to 
randomization
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 23 22 November 201611)Male subjects and female subjects of childbearing potential who engage in heterosexual 
intercourse must agree to use protocol specified method(s) of contraception as described in
Appendix 4
12) Female subjects must agree to refrain from egg donation and in vitro fertilization during 
treatment until at least [ADDRESS_238088] dose of SOF/VEL or [ADDRESS_238089]
13) Lactating females must agree to discontinue nursing before the study  drugs are administered
14)Male subjects must agree to refrain from sperm donation from the date of Screening until at 
least [ADDRESS_238090] dose of SOF/VEL , 
whichever occurs last
15)Subject must be able to comply  with the dosing instructions for study  drug administration 
and able to complete the study  schedule of assessments
4.3. Exclusion Criteria
Subjects who meet any of the following exclusion criteria are not to be enrolled in this study .
1)Current or prior history  of any  of the following:
a)Clinically  significant medical or ps ychiatric illness or subjects is currently under 
evaluation for a potentially  clinicall y significant illness (other than HCV or 
co-morbidities associated with advanced liver disease except as noted below) or an y other 
medical or ps ychiatric disorder that may interfere with subject treatment, assessment or 
compliance with the protocol  
b)Gastroi ntestinal disorder or post-operative condition that could interfere with the 
absorption of the study  drug 
c)Difficulty  with blood collection and/or poor venous access for the purposes of 
phlebotomy
d)Significant pulmonary  disease, significant cardiac disease or porph yria
e)Malignancy  within the [ADDRESS_238091] been cured b y surgical resection (basal cell skin cancer, etc.).  Subjects under 
evaluation for possible malignancy  are not eligible
f)Significant drug allergy  (such as anaph ylaxis or hepatotoxicity ) 
2)Any history  of organ transplant other than liver or kidney
3) Chronic liver disease of a non- HCV etiology  (eg, hemochromatosis, Wilson’s disease, alfa -1 
antitry psin deficiency , cholangitis)
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 24 22 November [ZIP_CODE])Inability  to exclude HCC by  [CONTACT_47429] 6 months of Day  1 (including indeterminate 
hepatic nodule meeting OPTN Class 5 criteria, defined b y arterial enhancement with washout 
on portal venous/delay ed phase OR rate of growth maximum diameter increase in the 
absence of ablative therapy  by 50% or more documented on serial magnetic resonance 
imaging ( MRI )or computed tomograph y (CT)obtained <6 month apart)
5) Alpha- fetoprotein (AFP) > [ADDRESS_238092]
6 months or during screening
6) Active spontaneous bacterial peritonitis at S creening
7)Infection requiring sy stemic antibiotics at the time of Screening
8) Evidence of fibrosing cholestatic hepatitis at Screening
9)Life threatening SAE during Screening
10)Active variceal bleeding within 6 months of Screening
11)Prior placement of a portosy stemic shunt (such as TI PS)
12)ECG with clinically  significant abnormalities
13)Laboratory parameters at Screening: 
a)Hemoglobin < 10 g/dL
b)Platelets < 30,000/L
c)ALT > 10 the upper limit of normal  (ULN)
d)AST > 10  ULN
e)Alkaline phosphatase > [ADDRESS_238093]
f)Sodium <125 mEq/L
g)Total bilirubin > 10 mg/dL
h) Creatinine clearance (CL cr) <30 mL  /min, as calculated by  [CONTACT_16424] -Gault equation 
{Cockcroft et al 1976 }using actual body  weight
14)Hepatitis B surface antigen positive (HBsAg +) at Screening
15)Infection with human immunodeficiency  virus (HIV)
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 25 22 November 201616)Clinically -relevant alcohol or drug abuse within 12 months of screening. A positive drug 
screen will exclude subjects unless it can be explained by  a prescribed medication; the 
diagnosis and prescription must be approved b y the Investigator.
17)Prior exposure to any HCV NS5A inhibitor
18)Current use of corticosteroids at any  dose >10 mg of prednisone/day  (or equivalent dose of 
corticosteroid)
19)Use of an y prohibited concomitant medications as described in Section 5.5
20)Use of GM -CSF, epoetin alfa or other hematopoi etic stimulating agents within 2 weeks of 
Screening.
21) M ale with pregnant female partner. 
22)History  of clinically  significant hemoglobinopathy (eg, sickle cell disease, thalassemia)
23)Contraindications to RBV therap y
24)Known hy persensitivity  to VEL , RBV, SOF , the metabolites, or formulation excipi[INVESTIGATOR_840]
25)Participation in a clinical study  with an investigational drug or biologic within [ADDRESS_238094] not had a liver transplant
26)Medical justification for any MELD exception points (such as for HCC, current 
hepatopulmonary  syndrome, intractable encephalopathy, or an y other reason)
27)History  of hepatopulmonary  syndrome
Exclusion criteria that are specific to subjects who have had a liver transplant
28)Recipi[INVESTIGATOR_841] o f ABO incompatible organ
29) Histological evidence of unresolved rejection of liver transplant
30)Patients who had evidence of HCC at time of transplant must be 5 years posttransplant with 
no evidence of recurrence at Screening
31)Use or planned use of T -cell deplet ing/masking antibodies, sy stemic antineoplastic agents or
cyclosporine >300mg/ day, oruse of any  prohibited medications listed in Section 5.4
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 26 22 November [ZIP_CODE]. INVESTIGA TIONAL  MEDICINAL PRODUCTS
5.1. Randomization, Blin ding and Treatment Codes
This is a multicenter, open label study .  All subjects enrolled will receive SOF/VEL and RBV for 
12 weeks.  There will be no randomization or blinding.
5.2. Description and Handling of SOF/VEL FDC
5.2.1. Formulation
The SOF/VEL (400/100 mg) tablets are pi[INVESTIGATOR_8745], diamond -shaped, film -coated tablets, debossed 
with “GSI” on one side and “7916” on the other side. In addition to the active ingredients, the 
SOF/VEL tablets contain copovidone, microcry stalline cellulose, croscarmellose sodium, 
magnesium stearate, polyviny l alcohol, titanium dioxide, poly ethylene gl ycol, talc, and iron 
oxide red.
5.2.2. Packaging and Labeling
SOF/VEL (400/100 mg) tablets are packaged in white, high densit y polyethylene (HDPE) 
bottles. Each bottle contains 28 tablets and poly ester packing material. Each bottle is encl osed 
with a white, continuous thread, child -resistant screw cap with an induction -sealed, 
aluminum -faced liner.
SOF/VEL bottles to be distributed to centers in participating countries shall be labeled to meet 
all applicable requirements of the [LOCATION_002] Food and Drug Administration (FDA), EU 
Guideline to Good Manufacturing Practice -Annex 13 (I nvestigational Medicinal Products), 
and/or other local regulations.
5.2.3. Storage and Handling
SOF/VEL tablets should be stored at controlled room temperature until re quired for 
administration.  Controlled room temperature is defined as 25°C (77°F); excursions are permitted 
between 15°C and 30°C (59°F to 86°F) . 
All drug products should be stored in a securel y locked area, accessible only to authorized site 
personnel. T o ensure the stability  of the study  drug and to ensure proper product identification, 
the drug product should not be stored in a container other than the container in which they  are 
supplied. Consideration should be given to handling, preparation, and disp osal through measures 
that minimize drug contact [CONTACT_10850] . Appropriate precautions should be followed to avoid 
direct ey e contact [CONTACT_199609]/VEL tablets.
Sufficient quantities of SOF/VEL to complete the entire stu dy will be shipped to the investigator 
or qualified designee from the [COMPANY_009] Supply  Management Team (or its designee).
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 27 22 November [ZIP_CODE].3. Description and Handling of Ribavirin (RBV)
5.3.1. Formulation
RBV tablets, 200 mg, are light blue, capsule -shaped, film -coated tablets debossed with “3RP” on 
one side and “200” on the other side. See package insert for further information.
The RBV tablets being supplied by  [CONTACT_199610] a US marketed formulation of RBV.
5.3.2. Packaging and Labeling
The RBV tablets are packaged in white, HDPE bot tles. Each bottle contains 168 tablets and 
rayon coil packing material and is enclosed with a white, continuous thread, child -resistant screw 
cap with an induction -sealed, aluminum -faced liner. 
All RBV bottles to be distributed to centers in the participating countries and shall be labeled to 
meet all applicable requirements of the US Food and Drug Administration (FDA), EU Guideline 
to Good Manufacturing Practices- Annex 13 (Investigational Medicinal Products), and/or other 
local regulations as applicable.
RBV tablets (200 mg) will be supplied by  [CONTACT_199611].
5.3.3. Storage and Handling
RBV tablets should be stored at 25 °C (77 °F); excursions are permitted between 15 and30°C 
(59and86°F).
All drug products should be stored in a securel y locked area, accessible only  to authorized site 
personnel. To ensure the stability  of the study  drug and to ensure proper product identification, 
the drug product should not be stored in a container other than the container in which they  are 
supplied. Consi deration should be given to handling, preparation, and disposal through measures 
that minimize drug contact [CONTACT_10850] . Appropriate precautions should be followed to avoid 
direct ey e contact [CONTACT_199612].
5.4. Dosage and A dministration of SOF/VEL andRBV
SOF/VEL 400/100 mg tablets will be administered once dail y.RBV 200 mg tablets will be 
administered twice daily  ata starting dose of 600 mg. RBV should be taken in a divided daily  
dose with food ( Table 5-1). If the starting dose is well -tolerated and the subject maintains a 
hemoglobin level above 10 g/dL without the need for significant growth factor support, the dose 
can be titrated up to a maximum of 1000 -1200 mg daily  (1000 mg for subjects weighing <75 kg 
and 1200 mg for subjects weighing ≥75 kg). If the starting dose is not well -tolerated, the dose 
should be reduced as necessary .
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 28 22 November 2016Table5-1. Suggested Dose Administration of RBV
Total Daily RBV dose AM dose PM dose
200mg 1 tablet --
400 mg 1 tablet 1 tablet
600 mg 1 tablet 2 tablets
800 mg 2 tablets 2 tablets
1000 m g 2 tablets 3 tablets
1200 m g 3 tablets 3 tablets
All subjects should be instructed to maintain approximately  the same dail y dosing interval 
between stud y drug doses. To aid compliance, it is suggested that SOF/VEL is administered with 
either the morning or evening dose of RBV with food.
For missed dose(s ) of SOF/VEL , subjects should be instructed to take the missed dose of study  
drug as soon as possible during the same day .  Subjects should be cautioned never to double the 
next dose of SOF/VEL with a missed dose under any  circumstances.  
For missed dose( s) of RBV, subjects should be instructed to take the missed dose(s) of study  
drug as soon as possible, unless more than [ADDRESS_238095] should be instructed to wait and take the nex t dose at the 
regularl y scheduled time. No more than the dail y dose of RBV should be taken on an y calendar 
day. Subjects should be cautioned never to double the next dose with a missed dose of study  drug 
under an y circumstances. 
No food restrictions apply to SOF/VEL . However as RBV must be taken with food hence it is 
suggested that when SOF/VEL is taken with RBV, both drugs should be taken together and with 
food for optimal adherence.
5.5. Prior and Concomitant Medications
Concomitant medications taken within [ADDRESS_238096] dose of study  drug ,need to be recorded in the source documents and eCRFs 
(including all blood products).
For subjects on a calcineurin inhibitor (eg, tacrolimus, sirolimus, everolimus) forposttransplant 
immunosuppression, drug levels should be measured as per the standard schedule (or as 
clinically  indicated) for dose management at the clinical site, and processed at the local
laboratory . Management of the immunosuppression is not part of the clinical protocol, but levels
and resulting dose adjustments will be recorded to assess whether the regimens required
adjustment in correlation with resolution of the HCV infection.
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 29 22 November 2016Chronic use of corticosteroids at any  dose > 10mg of prednisone/day (or equivalent dose of
corticosteroid) for maintenance of immunosuppression is prohibited from 28 day s prior to the 
Day 1 visit through the end of study  drug dosing . Use of steroids for the short term treatment of 
Acute Cellular Rejection (ACR) or other r easons is up to the discretion of the Investigator.
Investigational agents or devices for an y indication are prohibited from 28 days prior to the 
Day 1 
visit through the end of study  drug dosing.
Concomitant use of certain medications or herbal/natural sup plements (such as moderate to 
potent inducers of drug transporters or metabolizing enz ymes, eg, P-gp,CYP2B6, CYP2C8, or 
CYP3A) with the study  drug may  result in pharmacokinetic interactions resulting in increases or 
decreases in exposure of the study  drug or these medications.
Table 5-
2below contains examples of medications that are prohibited from [ADDRESS_238097]/package inserts of other medications for 
age-
related recommendations or contraindications related to their use.
Table5-2. Disallowed and Concomitant Medications to be Used with Caution
Drug Class Agents Disallowed Use with Caution
Acid Reducing AgentsaProton Pump Inhibitors, H2 -Receptor
Antagonists, Antacids
AnticonvulsantsbPhenytoin, Carbamazepi[INVESTIGATOR_050], Phenobarbital, 
Oxcarbazepi[INVESTIGATOR_199597], Rifabutin, Rifapentine
Cardiac Medications AmiodaronedDigoxine
Herbal/Natural
SupplementsbSt. John’s Wort, Echinacea, Milk thistle (ie, 
silymarin), Chinese herb sho -saiko -to(or 
Xiao -Shai-Hu-Tang)
HMG- CoA Reductase
InhibitorsfRosuvastatin ( ≤10 mg/day) , Atorvastatin
Other Bosentanb, Modafinil b, Sulfasalazinec, 
Methotrexatec
a Co-administration with proton pump inhibitors (PPIs) is not recommended. If it is considered necessary to co -administer, 
then SOF/VEL should be administered with food and taken [ADDRESS_238098] not exceed a dose of 40 mg famotidine or equivalent and can be taken simultaneo usly 
with SOF/VEL and/or staggered by 12 hours. Antacids that directly neutralize stomach acid (ie ,Tums, Maalox) may not be 
taken within 4 hours (before or after) of SOF/VEL administration.
b May result in a decrease in the concentration of study drugs.
c May result in an increase in the concentration of study drugs and/or concomitant medications
d May result in symptomatic bradycardia. Mechanism is not currently known. The use of amiodarone is prohibited from 
60days prior to Day 1 through the end of treatment
e Monitor for signs and symptoms of digoxin toxicity.
f Use with SOF/VEL may result in an increase in the concentration of rosuvastatin Titrate rosuvastatin dose carefully and use 
the lowest necessary dose; do not exceed rosuvastatin 10 mg/day. Use atorvastati n with caution and at the lowest necessary 
dose. Monitor for signs and symptoms of muscle weakness or myopathy, including rhabdomyolysis
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 30 22 November 2016Medications for disease conditions excluded from the protocol ( eg, HIV infection) are not listed
under this Concomitant Medication section and are disallowed in the study . Should subjects have 
a need to initiate treatment with any  excluded concomitant medication, the Medical Monitor 
must be consulted prior to initiation of the new medication. In instances where an excluded
medication is initiated prior to discussion with the Sponsor, the I nvestigator must notify  [COMPANY_009] 
as soon as he/she is aware of the use of the excluded medication.
Subjects may  not take any  approved HCV medications during their participation in the study  
period.
5.5.1Colony Stimulating Agents
Potential subjects may  not be treated with colon y stimulating agents (CSA) within 2 weeks of 
Screening toelevate hematology  laboratory  parameters to facilitate entry  into the study . Use 
during the stud yis allowed a s clinicall y indicated. Use should be captured as a concomitant 
medication.
If ery thropoiesis- stimulating agents (ESAs) are used during the study, the following guidelines 
should be adhere dto:
ESAs should not be initiated until the hemoglobin falls below 10 g/dL ,
Iron studies should be obtained prior to and during treatment with ESA,
Iron supplementation should be initiated for deficient patients and to maintain transferrin 
saturation at a level that will support ery thropoiesis,
Once an ESA is initiated, h
emoglobin levels and blood pressure must be monitored weekl y 
until the hemoglobin level stabilizes,
Treatment should target a hemoglobin level sufficient to avoid transfusion.
ESA dose should be titrated to treatment response ,
ESA dose should be reduced if the hemoglobin increases b y more than 1 g/dL  in a 2 week 
period,
ESA dose should not exceed those recommended for currentl y approved indications,
ESAs should not be used in patients at increased risk for thromboembolic events, 
cardiovascular events, inclu ding those with inadequately  controlled hy pertension, and in 
patients diagnosed with malignancies.
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 31 22 November [ZIP_CODE].6. Accountability forSOF/VEL +RBV
The investigator is responsible for ensuring adequate accountability  of all used and unused study  
drug bottles. This includes acknowledgement of receipt of each shipment of study  drug (quantity  
and condition). All used and unused study  drug bottles dispensed to subjects must be returned to 
the site.
SOF/VEL +RBV accountability  records will be provided to each study  site to:
Reco rd the date received and quantity  of study  drug kits
Record the date, subject number, subject initials, the study  drug kit number dispensed
Record the date, quantity of used and unused study  drug kits returned, along with the initials 
of the person recording the information.
5.6.1. Study Drug Return or Disposal
Refer to Section 9.1.7 for information on return and disposal of study  drugs.
SOF/VEL
Protocol GS -US-342-[ADDRESS_238099] research organization (CRO).
6.1. Subject Enrollment and Treatment Assignment
This is an open -label stud y.  An Interactive Web Response Sy stem (IWRS) will be employ ed to 
manage subject screening, subject enrollment, and study  drug dispensation and resuppl y.  
6.1.1. Screening Visit (Day -28 to Day 0)
Subjects will be screened within 28 day s prior toenrollment to determine eligibility  for 
participation in the study . The screening window can be extended to 42 days with Sponsor
approval for subjects with extenuating circumstances. The following will be performed and 
documented at screening:
Obtain written informe d consent
 
Determine inclusion and exclusion eligibility
Obtain medical history , including :
Hepatitis C treatment history :
■Regimen(s)
■ Dates of previous treatment(s)
■
Response to previous treatment ( eg, nonresponder, relapse, discontinuation including 
reason)
Liver transplant history
Perform 12- lead ECG
Liver Disease Assessment
Liver biopsy  and/or Fibrosc an results (if available )
[COMPANY_003]
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 33 22 November 2016Assess presence and severity of ascites and hepatic encephalopathy for CPT score
Diagnostic imaging (eg ,ultrasound or CT scan) should be performed to exclude the 
presence of HCC
Perform c omplete ph ysical examination 
Vital signs
Body weight and height
Record an y serious adverse events and all adverse events related to protocol mandated 
procedures occurring after signing of the consent form
Review of concomitant medications
Pregnancy  prevention counseling 
Obtain blood samples for :
Hematology
Chemistry
Coagulation tests
HCV RNA
Determination of genot ype and subt ype of HCV infection
Serum-hCG pregnancy test for females of childbearing potential onl y
HCV antibody , HIV 1/2 antibody , HBsAg, HBcAb, and Hepatitis B surface antibody
(HBsAb )
HbA1c
IL28B
Fibrotest®
Obtain urine sample for:
Urinaly sis
Urine Drug Screen
SOF/VEL
Protocol GS -US-342-[ADDRESS_238100] all serious adverse events (SAEs), as well as any adverse events 
related to protocol -mandated procedures on the adverse events case report form (CRF/eCRF).  
All other untoward medical occurrences observed during the screening period, including 
exacerbation or changes in medical history are to be captured on the medical history  CRF/eCRF.  
See S ection 7Adverse Events and Toxicity  Management for additional details.
Retests of Screening labs are permitted only  if the initial exclusionary  value was either due to a
sample processing error or due to extenuating circumstances such as intercurrent illness .
6.2. Treatment Phase: Treatment Assessments
6.2.1. Day [ADDRESS_238101] be 
completed on Day  1 prior to enrollment and dosing/dispensing:
Confirm eligibility
Perform complete ph ysical examination 
Vital signs 
Body weight 
Assessment of AEs and concomitant medications
Pregnancy  prevention counseling 
Assess presence and severity  of ascites and hepatic encephalopathy  for CPT score
Perform 12- lead ECG
Subject com pletes Health Related Quality of Life Questionnaire: SF -36, CLDQ -HCV, 
FACIT -F, and WPAI
Obtain blood samples for:
Hematology
Chemistry
Coagulation tests
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 35 22 November 2016HCV RNA
Viral sequencing
 
HBV DNA (only in subjects who are HBcAb+ at Screenin g)
Obtain urine samples for the following procedures:
Urinaly sis
Urine pregnancy test for females of childbearing potential only
6.2.2. Study Drug Administration
Dispense study  drugs as directed by  [CONTACT_8784]
Instruct the subject on the packaging, storage and administration of study  drug
Observe the subject taking the first dose of study  drugs and record the time of first dose and 
whether it was taken with or without food 
6.2.3. Week2 (3 days)
The following procedures/assessments are to be completed at this visit:
Vital signs
Body Weight
Assessment of AEs and concomitant medications
Assess presence and severity  of ascites and hepatic encephalopathy  for CPT score
Obtain blood samples for:
Hematology
Chemistry
Coagulation
[COMPANY_003]
[COMPANY_003]
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 36 22 November 2016HCV RNA
Viral sequencing 
Single PK 
Assess adherence with the study  drug dosing regimen including pi[INVESTIGATOR_692]
6.2.4. Weeks 4 and 8 ( 3 days)
Assess presence and severity  of ascites and hepatic encephalopathy  for CPT score
Vital signs
Body Weight
Assessment of AEs and concomitant medications
Pregnancy  prevention counseling
Obtain blood samples for :
Hematology
Chemistry
Coagulation
HCV RNA
Viral sequencing
Single PK 
HBV DNA (only in subjects who are HBcAb+ at Screening)
Obtain urine sample for:
Urine pregnancy  test for females of childbearing potential only
Review study  drug compliance with subject (subject should return all study  drug at these 
visits)
Dispense study  drug as directed by  [CONTACT_199613]/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 37 22 November [ZIP_CODE].2.5. Week 12 ( 3 days) or Early Termination
Perform complete physical examination 
Assess presence and severity  of ascites and hepatic encephalopathy  for CPT score
Vital signs
Body weight 
Assessment of AEs and concomitant medications
Pregnancy  prevention counseling 
Subject completes Health Related Quality  of Lif e Questionnaire: SF -36, CLDQ -HCV, 
FACIT -F, and WPAI
Obtain blood samples for:
Hematology
Chemistry
Coagulation tests
HCV RNA
Viral sequencing
Single PK 
HBV DNA (only in subjects who are HBcAb+ at Screening)
Obtain urine samples for the following procedures:
Urinaly sis
Urine pregnancy test for females of childbearing potential only
Review study  drug compliance
Subjects should return all bottles of study drug at the Week 12 Visit
[COMPANY_003]
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 38 22 November [ZIP_CODE].3. Posttreatment Assessments
6.3.1. 4- Week Posttreatment Visit (5 days)
Assess presence and severity  of ascites and hepatic encephalopathy  for CPT score
Vital signs
Body Weight
Assessment of AEs and concomitant medications
Pregnancy  prevention counseling 
Obtain blood samples for: 
Hematology
Chemistry
Coagulation
HCV RNA
Viral sequencing
HBV DNA (only in subjects who are HBcAb+ at Screening)
Obtain urine sample for:
Urine pregnancy test for females of childbearing potential only
6.3.2. 12 & 24 Week Posttreatment Visit (5 days)
Assess presence and severity  of ascites and hepatic encephalopathy  for CPT score
Vital signs
Body Weight
Perform s ymptom -directed phy sical examination
Pregnancy  prevention counseling
Subject completes Health Related Quality  of Life Questionnaire: SF -36, CLDQ -HCV,
FACIT -F, and WPAI at posttreatment Week 12 only
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 39 22 November 2016Obtain blood samples for :
Hematology
Chemistry
Coagulation
HCV RNA
Viral sequencing
HBV DNA (only in subjects who are HBcAb+ at Screening)
Obtain urine sample for:
Urine pregnancy test for females of childbearing potential only
6.4. Assessments for Premature Discontinuation from Study
If a subject discontinues study  drug (for example, as a result of an AE), every  attempt should be 
made to keep the subject in the study  and continue to pe rform the required study -related follow-
up and procedures (see Section 3.4.1
, Criteria for Discontinuation of Study Treatment ). If this is 
not possible or acceptable to the subject or Investigator, the subject may  be withdrawn from the 
study .
6.5. Procedures and Specifications
6.5.1. Clinical Laboratory Analytes
Hematology : Hematocrit, hemoglobin (Hb), platelet count, red blood cell count (RBC), white 
blood cell count (WBC) with differential (absolute and percentage) including l ymphocy tes, 
monocy tes, neutrophils, eos inophils, basophils, reticulocy te count and mean corpuscular volume 
(MCV).
Coagulation : International normalized r atio (I NR), prothrombin time (PT), activated partial 
thromboplastin time (APTT) 
Chemistry :Alanine aminotransferase (ALT/SGPT), aspartate aminotransferase (AST/SGOT), 
albumin, alkaline phosphatase, creatinine, total bilirubin and direct bilirubin, glucose, lipase, 
potassium, sodium, phosphate, uric acid, and creatine kinase (CK) , 
Urinaly sis: blood, glucose, leukocy te esterase, pH, protein, urobilinogen. R eflex to microscopic 
urinaly sis if dipstick result is abnormal.
Virological Tests: Serologies for HCV and HBV. HBV DNA (onl y in subjects who are 
HBcAb +at Screening). Serology  and/or antigen te sting for HIV (including reflex testing) as 
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 40 22 November 2016necessary , HCV RNA will be measured using the COBAS®AmpliPrep/COBAS®TaqMan®
HCV Test , v2.0 for Use with the High Pure S ystem. HCV genot ype and subty pe will be 
determined using the Siemens VERSANT®HCV Genoty pe INNO-LiPA 2.0 Assay . [COMPANY_009] 
reserves the right to use alternate assay s for HCV RNA and HCV genot ype should the above 
assay s become unavailable or the results are in conclusive .
IL28B genoty pe will be determined by  [CONTACT_940] (PCR) amplification of the 
SNP, rs12979860, with sequence specific forward and reverse primers and allele specific 
fluorescentl y labeled TaqMan®MGB probes. [COMPANY_009] reserves the rights to use alternate assay s 
for IL28B determination should the above assay  become unavailable.
Pregnancy  Tests : Serum  -hCG, Urine -hCG (if positive, requires immediate confirmation with 
Serum -hCG)
Additional Tests : Urine drug screen (for ampheta mines, cocaine, methadone, opi[INVESTIGATOR_858]), 
hemoglobin A1c (HbA1c), Fibrotest .
6.5.2. Medical History
Medical history  including details regarding illnesses and allergies, date(s) of onset, and whether 
condition(s) is currentl y ongoing, and medication history  will be collected on all subjects during 
screening. Obtain HCV treatment history  as per Section 4.
6.5.3. C omplete Physical Examination
A complete ph ysical examination must include source documentation of general appearance, and 
the following bod y systems: Head, neck and thy roid; ey es, ears, nose, throat, mouth and tongue; 
chest (excluding breasts); respi[INVESTIGATOR_696] ; cardiovascular; ly mph nodes, abdomen; skin, hair, nails; 
musculoskeletal; neurological. 
6.5.4. Height & Weight Measurement
Height will be collected at Screening . Weight measurement will be collected at each study  visit. 
The difference in bod y weight measuremen ts between Day  1 and End of Treatment will be 
calculated. 
6.5.5. Vital Signs
Assessment of vital signs will include measurement of resting blood pressure, pulse, respi[INVESTIGATOR_2865], and temperature.
Blood pressure will be measured using the following standardized process:
Subject should sit for 
5 minutes with feet flat on the floor and measurement arm supported 
so that the midpoint of the manometer cuff is at heart level;
Use a mercury  sphy gmomanometer or automatic blood pressure device with an appropriately  
sized cuff with the bladder centered over the brachial artery ;
Measure and record the blood pressure to the nearest [ADDRESS_238102] whole number on an automatic device.
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 41 22 November [ZIP_CODE].5.6. Body Mass Index (BMI)
BMI is calculated b y the following equation.
BMI =weight (pounds) 703           or            weight in kilograms
   (height in inches)2                                (height in meters)2
6.5.7. MELD and CPT Score Calculations
MEL D score and CPT score will be calculated from the central laboratory  values attained at each 
visit. Assessment of ascites and hepatic encephalopathy  will be determined by  [CONTACT_199614]. Besides calculating the CPT score at Screening 
(using central laboratory  values) to determine eligibility , sites will not need to calculate these 
scores for subsequent visits.
[IP_ADDRESS]. MEL DScore
The MELD score is calculated using the following formula {
MELD/PELD 2009 }:
MEL D = 3.8[serum bilirubin (mg/dL)] + 11.2[INR] + 9.57[serum creatinine *(mg/dL)] + 6.[ADDRESS_238103] whole number. Laboratory  values less than 1.0 are set to 1.0 for the 
purposes of the MELD score calculation.
* If subject has had dial ysis twice within a week prior to the serum creatinine measurement, or is 
within 24 hours of continuous venovenous hemodiafiltration, then default to 4 mg/dL for serum 
creatinine value in MEL D calculation.
[IP_ADDRESS]. CPT Score
Child -Pugh -Turcotte score should be assessed at all visits per Table 6-1.  
Table6-1. Child-Pugh-Turcotte Classification of the severity of cirrhosis
[ADDRESS_238104] is receiving 
medical therapy for HE  Medication -Refractory
Marked 
confusion/incoherent, 
rousable b ut sleepi[INVESTIGATOR_199598]/Moderate
Cross sectional imaging 
showing ascites
   
Abdominal distension 
  
Medication for ascitesSevere
(diuretic-refractory)
Visible clinically
Bilirubin (mg/dL) < 2 2-3 > 3
Albumin (g/dL) > 3.5 2.8-3.5 < 2.8
INR < 1.7 1.7-2.3 > 2.3
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 42 22 November 2016CPT score is obtained by [CONTACT_199615].
CPT class : A = 5 -6 points
B = 7 -9 points
C = 10- 15 points
Records of c oncomitant medications for ascites and hepatic encephalopathy  will be collected in 
the CRF.  
6.5.8. Creatinine Clearance
Creatinine clearance is calculated b y the Cockcroft -Gault equation {Cockcroft et al 1976 }.
Male: CL Cr(mL/min) = [
140 − age (y ears)] BW(kg)
72SCr
Female: CL Cr(mL/min) =[140 −age (y ears)] BW(kg) 0.85
72SCr
SCr= serum cr eatinine (mg/dL)
Actual bod y weight will be used for the CL Cr.
6.5.9. 12- Lead ECG
Subjects will be required to rest in a supi[INVESTIGATOR_19636] ≥ 5 minutes prior to making a recording.
The investigator (or qualified designee) should review the ECG traces recorded in real time for 
clinically  significant abnormalities.  On treatment ECGs should be compared to the subject’s 
Day 1 as part of routine safet y monitoring.
6.5.10. Viral Sequencing (Archive)
Plasma samples will be collected at Day 1 and each subsequent visit for viral sequence anal ysis. 
At any  unscheduled visit initiated for the purpose of confirming HCV virologic breakthrough, 
HCV viral sequencing/phenoty pe plasma sample must also be collected.  Unused samples may  
be archived.
6.5.11. Single Pharmacokinetic (PK) Sample
Single PK blood samples will be collected for all subjects at each on -treatment visit and archi ved
for PK anal ysis of SOF (and metabolites) VEL and RBV .
6.5.12. HBV DNA Sample
A sampl e for HBV DNA testing will be collected at on- treatment visits at Day  1 and at Weeks 4, 
8, and 12 or Early Termination and all posttreatment visits.  HBV DNA will only be tested in 
subjects who are HBcAb + at Screening to monitor for HBV re -activation .  
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 43 22 November [ZIP_CODE].5.13. IL28B Testing
A blood sample will be obtained at Screening for specific genetic analy sis of the rs12979860 
(IL28B) genetic variant.
6.5.14. Archive Plasma Sample
 
 
 
 
 
 
 
 
 
 
  
 
 
 
6.5.16. Pregnancy Testing
Female subjects of childbearing potential should be provided with Urine Pregnancy  test kits, 
instructed on their use, and requested to continue to self -monitor for pregnancy  between 
scheduled stud y visits, every [ADDRESS_238105]. 
6.5.17. Health Related Quality of Life Survey
A health related quality of life survey , SF-36, CLDQ -HCV, FACIT- F, and WPAI , will be 
completed b y patients at Day  1, Week 12 and posttreatment Week 12, and Earl y Termination (if 
appropriate).  The subject should read the questionnaire by  [CONTACT_199616]/herself and write/mark 
answers dir ectly onto the questionnaire.
[COMPANY_003]
[COMPANY_003]
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 44 22 November [ZIP_CODE]. ADVERSE EVENTS AND TOXICITY  MANAGEMENT
7.1. Definitions of Adverse Events, Adverse Reactions, and Serious Adverse 
Events
7.1.1. Adverse Events
An adverse event (AE) is any  untoward medical occurrence in a clinical study  subject 
administer ed a medicinal product ,which does not necessarily  have a causal relationship with th e
treatment. An AE can therefore be an y unfavorable and/or unintended sign, sy mptom, or disease 
temporally  associated with the use of a medicinal product, whether or not c onsidered related to 
the medicinal product. AEs may  also include pre -or posttreatment complications that occur as a 
result of protocol specified procedures, overdose, drug abuse/misuse reports , or occupational 
exposure . Preexisting events that increase in severity  or change in nature during or as a 
consequence of participation in the clinical study  will also be considered AEs.
An AE does not include the following:
Medical or surgical procedures such as surgery , endoscopy , tooth extraction, andtransfusion.
T
he condition that led to the procedure may be an adverse event and must be reported
Pre-existing diseases, conditions, or laboratory  abnormalities present or detected before the 
screening visit that do not worsen
Situations where an untoward medical occu rrence has not occurred (eg, hospi[INVESTIGATOR_10800] , social and/or convenience admissions)
Overdose without clinical sequelae (see Section 7.6.1 )
Any medical condition or clinically  significant laboratory  abnormality  with an onset date 
before the consent form is signed and not related to a protocol- associated procedure is not an 
AE. I t is considered to be pre -existing and should be documented on the medical history  
CRF.
7.1.2. Serious Adverse Events
A serious adverse event (SAE) is defined as an even t that, at an y dose, results in the following:
Death
Life-threatening (Note: The term “life -threatening” in the definition of “serious” refers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event tha t hypotheticall y might have caused death if it were more severe)
In-patient hospi[INVESTIGATOR_1081]
Persistent or significant disability /incapacit y
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 45 22 November 2016A congenital anomal y/birth defect
A medicall y important event or reactio n: such events may  not be immediately  
life-threatening or result in death or hospi[INVESTIGATOR_82221]. Medical and 
scientific judgment must be exercised to determine whether such an event is a reportable 
under expedited reporting rules. Examples of medically important events include intensive 
treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059]; and development of drug dependency  or 
drug abuse. For the avoidance of doubt, infections resulting from contaminated medicinal 
product will be considered a medicall y important event and subject to expedited reporting 
requirements.
7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory  abnormalities without clinical significance are not recorded as AEs or SAEs. 
However, laboratory  abnormalities ( eg, clinical c hemistry , hematology , and urinaly sis) that 
require medical or surgical intervention or lead to study  drug interruption, modification, or 
discontinuation must be recorded as an AE, as well as an SAE, if applicable. I n addition, 
laboratory  or other abnormal assessments ( eg, electrocardiogram, x -rays, vital signs) that are 
associated with signs and/or symptoms must be recorded as an AE or SAE if they  meet the 
definition of an AE or SAE as described in Sections 7.1.[ADDRESS_238106] the s yndrome or diagnosis ( eg, anemia), not the 
laboratory  result ( ie, decreased hemoglobin).
For specific information on handling of clinical laboratory  abnormalities in this study , please 
refer to Section 7.5
7.2. Assessment of Adve rse Events and Serious Adverse Events
The investigator or qualified sub
-investigator is responsible for assessing AEs and SAEs for 
causality  and severity , and for final review and confirmation of accuracy  of event information 
and assessments.
7.2.1. Assessment of Causality for Study Drugs and Procedures
The investigator or qualified subinvestigator is responsible for assessing the relationship to study  
drug therapy  using clinical judgment and the following considerations:
No: Evidence exists that the adverse event has an etiology  other than the study  drug . For 
SAEs, an alternative causality  must be provided ( eg, pre-existing condition, underly ing 
disease, intercurrent illness, or concomitant medication).
Yes:There is reasonable possibility  that the event may  have been caused by [CONTACT_10853].
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 46 22 November 2016It should be emphasized that ineffective treatment should not be considered as causall y related in 
the context of adverse event reporting. 
The relationship to study  procedures ( eg, invasive procedures such as venipuncture or biops y) 
should be assessed using the following considerations:
No: Evidence exists that the adverse event has an etiology  other than the study procedure
Yes: The adverse event occurred as a result of protocol procedures (eg, venipun cture )
7.2.2. Assessment of Severity
The severit y grading of AEs will be assessed as Grade 1, 2, 3, or 4 using the GSI Grading Scale 
for Severit y of Adverse Events and Laboratory Abnormalities ( Appendix 3). For AEs associated 
with laboratory  abnormalities, the e vent should be graded on the basis of the clinical severity  in 
the context of the underly ing conditions; this may or may  not be in agreement with the grading 
of the laboratory  abnormality .
7.3. Investigator Requirements and Instructions for Reporting Adverse Ev ents 
and Serious Adverse Events to [COMPANY_009]
Requirements for collection prior to study  drug initiation:
After informed consent, but prior to initiation of study  drug , the following ty pes of events should 
be reported on the case report form (CRF/eCRF): all SAEs , regardless of cause or relationship,
and adverse events related to protocol- mandated procedures.
7.3.1. Adverse Events
Following initiation of study  drug , collect a ll AEs, regardless of cause or relationship, until 
30daysafter last administration of study drug and report to the CRF/eCRF database as 
instructed.
All AEs should be followed up until resolution or until the adverse event is stable, if possible. 
[COMPANY_009] Sciences may  request that certain AEs be followed bey ond the protocol defined follow up 
period
.
7.3.2. Serious Adverse Events
All SAEs, regardless of cause or relationship, that occur after the subject first consents to 
participate in the stud y (ie, signing the informed consent) and throughout the duration of the 
study , including the protocol -required posttreatment follow -up period, must be reported to the 
CRF/eCRF database and [COMPANY_009] Drug Safet y and Public Health (DSPH) as instructed. This also 
includes an y SAEs resulting from protocol- associated procedures performed 
after informed 
consent is signed.
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 47 22 November 2016Investigators are not obligated to activel y seek SAEs after the protocol defined follow up period;
however, if the investigator learns of an y SAEs that occur after stud y participation has concluded 
and the event is deemed relevant to the use of study  drug , he/she should promptly  document and 
report the event to [COMPANY_009] DSPH.
All AEs and SAEs will be recorded in the eCRF database within the timelines outlined in the 
eCRF completion guideline. 
Electronic Serious Adverse Event (eSAE) Reporting Process
Site personnel record all SAE data in the eCRF database and from there transmit the SAE 
information to [COMPANY_009] DSPH within 24 hours of the investigator’s knowledge of the event. 
Detailed instructions can be found in the eCRF completion guidelines.
If for an y reason it is not possible to record the SAE information electronically  (ie, the e CRF 
database is not functioning) record t he SAE on the paper serious adv erse event reporting 
form and submit within 24 hours to:
[COMPANY_009] Sciences, DSPH : Fax:
E
-mail:
As soon as it is possible to do so, any SAE reported via paper must be transcribed into the 
eCRF Database according to instructions in the eCRF completion guidelines.
If an SAE has been reported via a paper form because the eCRF database has been locked, no 
further action is necessary.
For fatal or life -threatening events, copi[INVESTIGATOR_3103], autops y reports, and other 
documents are also to be submitted by  e-mail or fax when requested and applicable. 
Transmission of such documents should occur without personal subject identification, 
maintaining the traceability  of a document to the subject identifiers.
Additional information may  be requested to ensure the timely  completion of accurate safet y 
reports.
Any medicati ons necessary  for treatment of the SAE must be recorded onto the concomitant 
medication section of the subject’s CRF/eCRF and the event description section of the SAE 
form.
Medical Monitor contact [CONTACT_10856]:
[COMPANY_009] Medical Monitor:
Telephone:
Fax:
Email:
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 48 22 November [ZIP_CODE].4. [COMPANY_009] Reporting Requirements
Depending on relevant local legislation or regulations, including the applicable US FDA Code of 
Federal Regulations, the EU Clinical Tr ials Directive (2001/20/EC) and relevant updates, and 
other country -specific legislation or regulations, [COMPANY_009] may be required to expedite to 
worldwide regulatory  agencies reports of SAEs, serious adverse drug reactions (SADRs), or 
suspected unexpected se rious adverse reactions (S[LOCATION_003]Rs). I n accordance with the EU Clinical 
Trials Directive (2001/20/EC), [COMPANY_009] or a specified designee will notify worldwide regulatory  
agencies and the relevant I EC in concerned Member States of applicable S[LOCATION_003]Rs as outlined in
current regulations.
Assessment of expectedness for SAEs will be determined by  [CONTACT_143367]’s brochure or relevant local label as applicable. 
All investigators will receive a safet y letter notify ing them of relevant S[LOCATION_003]R reports associated 
with any  study  drug . The investigator should notify  the IRB or IEC of S[LOCATION_003]R reports as soon as 
is practical, where this is required b y local regulatory agencies, and in accordance with the local 
institutional p olicy . 
7.5. Toxicity Management
7.5.1. Dose Adjustments
There is no option of SOF/VEL dose reduction due to toxicity .  If SOF/VEL is withheld due to 
toxicity , the subject must discontinue treatment and complete an Earl y Termination (ET) visit.
Dose reduction or discontinuation of RBV due to toxicity  is allowed at the discretion of the 
investigator. Once discontinued or reduced, the RBV dosing may  be restarted or increased to the 
starting dose at the discretion of the investigator. RBV may  be permanently  discontin ued due to 
toxicity  without stoppi[INVESTIGATOR_199599]/VEL FDC.
7.5.2. Management of Rejection
The diagnosis of ACR, based on liver biops y, and the decision to treat are important concerns 
due to the potential interactions between immunosuppression and the success of HCV treat ment. 
It is expected that this will not be a common occurrence in this study , given that subjects must be 
stable and at least 6 months from transplant at study  entry . Sites will be asked to follow their 
institutional guidelines for the management of organ rejection, but to also give consideration to 
the following issues as related to this study  protocol. (This information is provided for guidance 
and consistency  across subjects, but variations will not be considered protocol violations if the 
treatment is c onsistent with the guidelines of the institution).
It is important to use standard criteria for diagnosis of rejection, to avoid over -
treatment of 
milder grades of rejection with corticosteroids whenever possible, and to standardize the 
exposure to cortico steroids when treatment for rejection is necessary
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 49 22 November 2016Epi[INVESTIGATOR_199600] y will be graded (grading b y 
Banff criteria, Appendix 3)
It is preferred that mild ACR is to be treated with upward adjustment of maintenance 
immunosuppression rather than the addition of corticosteroids
Cases of moderate or severe ACR may  require treatment with corticosteroids
Cases of presumptive rejection should be confirmed by [CONTACT_145139] (as per standard practice) 
if more than one dose of co rticosteroid is required
Subjects with steroid- resistant ACR should be discontinued from the study  so that 
management of their organ rejection can be the primary  focus of treatment.
7.6. Special Situations Reports
7.6.1. Definitions of Special Situations
Special situa tion reports include all reports of medication error, abuse, misuse, overdose, reports 
of adverse events associated with product complaints, occupational exposure with an AE, 
pregnancy  reports regardless of an associated AE and AE in an infant following ex posure from 
breastfeeding.
Medication error is an
y unintentional error in the prescribing, dispensing, or administration of a 
medicinal product while in the control of the health care provider, subject, or consumer.
Abuse is defined as persistent or spora dic intentional excessive use of a medicinal product by  a 
subject.
Misuse is defined as an y intentional andinappropriate use of a medicinal product that is not in 
accordance with the protocol instructions or the local prescribing information.
An overdose is defined as an accidental or intentional administration of a quantity  of a medicinal 
product given per administration or cumulatively  which is above the maximum recommended 
dose as per protocol or in the product labelling (as it applies to the daily  dose of the subject in 
question). In cases of a discrepancy  in drug accountability , overdose will be established only  
when it is clear that the subject has taken the excess dose(s). Overdose cannot be established 
when the subject cannot account for the discrep ancy  except in cases in which the investigator has 
reason to suspect that the subject has taken the additional dose(s).
Product complaint is defined as complaints arising from potential deviations in the manufacture, 
packaging, or distribution of the medicinal product.  
Occupational exposure with an AE is defined as exposure to a medicinal product as a result of 
one’s professional or non -professional occupation
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 50 22 November [ZIP_CODE].6.2. Instructions for Reporting Special Situations
[IP_ADDRESS]. Instructions for Reporting Pregnancies
The investigator should report pregnancies in female study  subjects that are identified after 
initiation of study  drug and throughout the stud y, including the post study drug follow -up period, 
to[COMPANY_009] DSPH using the pregnancy  report form within 24 hours of becoming aware of the 
pregnancy .
Refer to S ection 7.3and the CRF/eCRF completion guidelines for full instructions on the 
mechanism of pregnancy reporting.
The pregnancy  itself is not considered an AE nor is an induced elective abortion to terminate a 
pregnancy  without medical reasons.
Any premature termination of pregnancy  (eg, a spontaneous abortion, an induced therapeutic 
abortion due to complications or other medical reasons) must be reported within [ADDRESS_238107] information is as follows: Email: 
 and Fax:  
Pregnancies of female partners of male stud y subjects exposed to [COMPANY_009] or other study  drugs 
must also be reported and relevant information should be submitted to [COMPANY_009] DSPH using the 
pregnancy  and pregnancy  outcome forms within [ADDRESS_238108] should 
continue until the conclusion of the pregnancy . If the end of the pregnancy  occurs after the study  
has been completed, the outcome should be reported directl y to [COMPANY_009] DSPH, fax number 
 or email 
Refer to Appendix 4for Pregnancy  Precautions, Definition for Female of Childbearing Potential, 
and Contraceptive Requirements
.
[IP_ADDRESS]. Reporting Requirements for L iver Transplant and Complications of L iver 
Transplant
If the liver transplant procedure occu rs within the AE collection window ([ADDRESS_238109] 
dose of study  drug), due to the nature of the subject population and the inclusion criteria, events 
that are clearl y related to liver transplant should not be collected as an AE or SAE.  In additio n, 
these events will be exempt from global expedited reporting requirements for the duration of the 
study . These include:
a)The liver transplant procedure itself (and related hospi[INVESTIGATOR_059])
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 51 22 November 2016b)Events that are direct sequelae of the liver transplant (such as s urgical complications) or 
peri-operative care (central line insertions, etc.)
c)Planned hospi[INVESTIGATOR_199601]/SAEs only  if it is assessed that the events were not an 
anticipated or predictable part of the transplant process or procedure. In addition, concomitant 
medications related to the transplant procedure do not need to be recorded (anesthetics, 
peri-operative pain medicatio n, etc ). If there are any  questions about how an event should be 
reported, please contact [CONTACT_40862].
[IP_ADDRESS]. Reporting Other Special Situations
All other special situation reports must be reported on the special situations report form and 
forwarded toor [COMPANY_009] DSPH within [ADDRESS_238110] of situations that involve study  drug and/or [COMPANY_009] 
concomitant medications , but do not apply
 to non-[COMPANY_009] concomitant medications. 
Special situations involving non-[COMPANY_009] concomitant medications does not need to be reported on 
the special situ ations report form; however, for special situations that result in AEs due to a 
non-
[COMPANY_009] concomitant medication, the AE should be reported on the AE form . 
Any inappropriate use of concomitant medications prohibited by  [CONTACT_10857] “misuse,” but may  be more appropriately  documented as a protocol deviation.
Refer to S ection 7.3and the CRF/eCRF completion guidelines for full instructions on the 
mechanism of special situations reporting.
All clinical sequelae in relation to these special situation reports will be reported as AEs or SAEs 
at the same time using the AE CRF/eCRF and/or the SAE report form. Details of the sy mptoms 
and signs, clinical management, and outcome will be reported, when available.
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 52 22 November [ZIP_CODE]. STATISTICAL  CONSIDER ATIONS
8.1. Analysis Objectives and Endpoints
8.1.1. Analysis Objectives
The primary  objectives of this study  are:
To evaluate the efficacy  of treatment with sofosbuvir (SOF)/velpatasvir (VEL) fixed -dose 
combination (FDC) with ribavirin (RBV) for 12 weeks  in subjects with chronic HCV 
infection and Child- Pugh -Turcotte (CPT) class C cirrhosis as measured b y the proporti on of 
subjects with sustained viral response 12 weeks after cessation of treatment (SVR12)
To evaluate the safet y and tolerability  of the treatment regimen 
The secondary  objectives of this study  are:
To determine the proportion of subjects who attain SVR at 4and 24 weeks after cessation of 
the study  treatment regimen (SVR4 and SVR24) 
To evaluate the proportion of subjects with virologic failure
To evaluate therapeutic efficacy  as measured b y the change of CPT score and MEL D score
To evaluate the kinetics of circulating HCV RNA during treatment and after cessation 
treatment
To evaluate the emergence of viral resistance to SOF and VEL during treatment and after 
cessation of treatment
The exploratory  objectives of this study  are:
 
 
 
8.1.2. Primary Endpoint
The primary  efficacy  endpoint is SVR 12 (HCV RNA < LLOQ 12 weeks after cessation of stud y 
treatment regimen) in the Full Anal ysis Set (FAS).
The primary  safety endpoint is any AE that led to permanent discontinuation of study  drug.
[COMPANY_003]
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 53 22 November [ZIP_CODE].1.3. Secondary Endpoint
The secondary  efficacy  endpoints include the proportion of subjects who attain sustained 
virologic response at 4 and 24 weeks after cessation of the study treatment regimen (SVR4 and 
SVR24); the proportion of subjects who have HCV RNA < LLOQ b y visit while on study  
treatment; CPT and MELD score changes from Day 1; absolute and change from Day  1 in HCV 
RNA through Week 12; and the proportion of subjects with virologic failure.
8.1.4. Other Endpoints of Interest
Other endpoint sof interest may include ALT normalization and change in HRQoL  parameters.
8.2. Analysis Conventions
All individual subject data will be listed as measured. All statistical summaries and anal yses will 
be performed using SA Ssoftware (SAS Institute, Cary , North Carolina, [LOCATION_003]).
The study  drug sin this study areSOF/ VEL + RBV . Last dose of the 
study drug refers to the last 
dose of SOF/VEL and RBV andwill be used in the definition of treatment -emergent AEs and 
laboratory  abno rmalities as well as the efficacy endpoints of SVR at various posttreatment
timepoints.
8.2.1. Analysis Sets
[IP_ADDRESS]. Efficacy Anal ysis Set
The anal ysis set for antiviral activity  analyses isdefined as the Full Anal ysis Set (FAS) which 
includes all enrolled subjects who received at least 1 dose of the study  drug.
[IP_ADDRESS]. Safety Anal ysis Set
The primary  anal ysis set for safety
 anal yses willbe Safet y Anal ysis Set which include s all
subjects who took at least [ADDRESS_238111] dose of the study  drug plus 30 day s.
[IP_ADDRESS]. Pharmacokinetics Analy sis Sets
The Pharmacokinetic ( PK) Anal ysis Set includes all enrolled subjects who took at least [ADDRESS_238112] may  include SOF (and its metabolites GS -566500 and 
GS-331007), VEL , and RBV . The PK A nalysis Set will be used for anal ysis of general PK.
SOF/VEL
Protocol GS -US-342-[ADDRESS_238113] dose.
If a data point is missing and is preceded and followed in time by  [CONTACT_199617] “< LLOQ target 
not detected (TND),” then the missing data point will be set to “< LLOQ TND.” If a data point is 
missing and preceded and followed b y values that are “< LLOQ detected,” or preceded b y
“<LLOQ detected” and followed by  “< LLOQ TND,” or preceded by  “<LLOQ TND” and 
followed b y “< LLOQ detected,” then the missing value will be set to “< LLOQ detected.” In
these situations the data point will be termed a bracketed success; otherwise, the data point will
be termed a bracketed failure ( ie, ≥ LLOQ detected) . If a data point is missing and is not
bracketed, the missing data point will also be termed a failure ( ie, ≥ LLOQ detected).
Where appropriate, safety  data for subjects that did not complete the study  will be included in 
summary  statistics. For example,
If a subject took at least [ADDRESS_238114] will be included in a summary  of 
AEs according to the treatment received; otherwise, if the subject is not dosed, then they  will 
be excluded from the summary .
If safety  laboratory  results for a subject are missing for an y reason at a time point, the subject 
will be excluded from the calculation of summary statistics for that time point. I f the subject 
is missing a pre -dose value, then the subject will be excluded from the calculation of 
summary  statistics for the predose value and the change from predose values.
Values for missing safety laboratory  data will not be imputed; however, a missing Day 1 result 
will be replaced with a screening result, if available. If no pretreatment laboratory  value i s 
available, the Day  1 value wi ll be assumed to be normal (ie , no grade [Grade 0]) for the summary  
of graded laboratory  abnormalities.
Values for missing vital signs data will not be imputed; however, a missing Day  1 result will be 
replaced with a screening result, if available.
HCV RNA values below the LLOQ for the assay  will be set to the lower limit minus 1 for 
calculation of summary
 statistics for the actual HCV RNA values and the change from Day  1 
values by  [CONTACT_154023]. The reported values will be pro vided in the HCV RNA listing.
For selected anal yses of earl y time point data, HCV RNA data (IU/mL) may be transformed to 
the logarithmic (base 10) scale (log 10IU/mL).
SOF/VEL
Protocol GS -US-342-[ADDRESS_238115] descriptive 
methods.
Demographic data will include sex, self-identified race/ethnicit y.
Baseline characteristic data will include body  mass index, HCV RNA level (log 10IU/mL), 
genot ype of HCV infection, IL28B genoty pe,CPT score ,MELD score and additional endpoints 
as necessary .
8.4. Efficacy Analysis
8.4.1. Primary Analysis
The primary  efficacy  endpoint for this study  will be the proportion of subjects with SV R12, 
defined as HCV RNA < LLOQ 12 weeks after cessation of the study  treatme nt regimen in the 
FAS population.  Point estimate and 95% confidence interval (using the Clopper -Pearson 
method) of SV R12 will be computed.
8.4.2. Secondary Analyses
The proportion of subjects with HCV RNA below the LLOQ over time (including SVR4 and 
SVR24) will be presented in tabular and graphical form. Descriptive summaries and listings will 
be provided for additional efficacy  evaluations of the proportion of subje cts who experience 
virologic failure, serum HCV RNA actual values and change from baseline , and other endpoint
of interest including ALT normalization.
 
 
 
 
Details on efficacy  anal yses will be described in the statistical anal ysis plan.
8.5. Safety Analysis
Safety  will be evaluated by  [CONTACT_199618], phy sical examinations, vital
signs measurements and AEs which will bedocumented at various time points during the study .
All safet y data collected on or after the first dose of the study  drug administr ation up to [ADDRESS_238116] dose of the study  drug will be summarized .
[COMPANY_003]
SOF/VEL
Protocol GS -US-342-[ADDRESS_238117]’s extent of exposure to the study  drug will be generated from the study  drug 
administration page of eCRF . Exposure data will be summarized. 
8.5.2. AdverseEvents
Clinical and laboratory  adverse events will be coded using the Medical Dictionary  for 
Regulatory  Activities (MedDRA). Sy stem Organ Class (SOC), High -Level Group Term 
(HLGT), High -Level Term (HL T), Preferred Term (PT), and Lower -Level Term (LLT) will be 
attached to the clinical database.
Events will be summarized on the basis of the date of onset for the event. A treatment -emergent 
adverse event will be defined as an y adverse event with an onset date on or after the stud y drug 
start date and no later than 30 day s after permanent discontinuation of the study  drug or any  
adverse event leading to premature discontinuation of the study  drug .
Summaries (number and percentage of subjects) of treatment -emergent adverse events (b y SOC 
and PT) will be provided for:
All AEs
AEs of Grade 3 or above
AEs of Grade 2 or above
All treatment -related AEs
Treatment -related AEs of Grade 3 or above
Treatment -related AEs of Grade 2 or above
All SAEs
All treatment -related SAEs
All AEs leading to premature discontinuation of the study  drug
Deaths
All AEs colle cted during the study  will be presented in the data listings
8.5.3. Laboratory Evaluations
Selected laboratory  data (using conventional units) will be summarized (n, mean, SD, median, 
Q1, Q3, minimum, and maximum) by  [CONTACT_199619] /Day  1.
SOF/VEL
Protocol GS -US-342-[ADDRESS_238118] dose of study  drug plus 30 dayswill be summarized .
Values for missing safety laboratory  data will not be imputed; however, a missing 
Baseline/Day 1 result will be replaced with a screening result, if available. If no pretreatment 
laboratory  value is available, the baseline value wi ll be assumed to be normal (ie, no grade 
[Grade 0]) for the summary  of graded laboratory  abnormalities
.If Baseline/Day  [ADDRESS_238119] -baseline graded abnormality  (ie, at least Grade 1) will be considered 
treatment emergent.
All laboratory  abnormalities will be included in the listings of laboratory  data .
8.5.4. Other Safety Evaluations
Individual data and change from baseline for vital signs measurements will be listed by  [CONTACT_199620] (n, mean, SD, median, Q1, Q3, minimum, 
and maximum).
8.6. Pharmacokinetic Analysis
Concentrations of SOF (and its metabolites GS-566500 and GS -331007), VEL , and RBV in 
plasma may be determined using validated bioanaly tical assay s and listed.
8.7. Sample Size
Due to the exploratory  nature of this study , no formal power calculations were used to determine 
sample size. The sample size i s selected for practical reasons.
With a sample size of approximately  50 subjects, a 2-sided 95% exact confidence interval of the 
SVR12 rate will extend at most 29% in length.
SOF/VEL
Protocol GS -US-342-[ADDRESS_238120] igator will ensure that this study  is conducted in accordance with the principles of the 
Declaration of Helsinki (as amended in Edinburgh, Toky o, Venice, Hong Kong, and 
South Africa), International Conference on Harmonisation (ICH) guidelines, or with the laws and 
regulations of the country in which the research is conducted, whichever affords the greater 
protection to the study  subject. These standards are consistent with the European Union Clinical 
Trials Directive 2001/20/EC and Good Clinical Practice Di rective 2005/28/EC.
The investigator will ensure adherence to the basic principles of Good Clinical Practice, as 
outlined in 21 CFR 312, subpart D, “Responsibilities of Sponsors and Investigators,” [ADDRESS_238121] be provided prior to 
the investigator’s (and any  subinvestigator’s) participation in the study . The investigator and 
subinvestigator agree to notify  [COMPANY_009] of an y change in reportable interests during the stud y and 
for [ADDRESS_238122] (IRB)/Independent Ethics Committee (IEC) 
Review and Approval
The investigator (or sponsor as appropriate according to local regulations) will submit this 
protocol, informed consent form, and an y accompanying material to be provided to the subject 
(such as advertisements, subject information sheets, or descriptions of the study  used to obtain 
informed consent) to an IRB /IEC. The investigator will not begin an y study subject activities 
until approval from the IRB/IEC has been documented and provided as a letter to the 
investigator.
Before implementation, the investigator will submit to and receive documented approval from
the IRB/IEC an y modifications made to the protocol or any accompan ying material to be 
provided to the subject after initial IRB/IEC approval, with the exception of those necessary  to 
reduce immediate risk to study  subjects.
9.1.3. Informed Consent
The investigat or is responsible for obtaining written informed consent from each individual 
participating in this study after adequate explanation of the aims, methods, objectives, and 
potential hazards of the study  and before undertaking an y stud y-related procedures. T he 
SOF/VEL
Protocol GS -US-342-[ADDRESS_238123] current IRB or IEC-approved consent form for documenting 
written informed consent. Each informed consent (or assent as applicable) will be appropriatel y 
signed and dated b y the subject or the subject’s legally authorized representative and the person 
conducting the consent discussion, and also by  [CONTACT_199621].
9.1.4. Confidentiality
The investigator must assure that subjects’ anon ymity  will be strictly  maintained and th at their 
identities are protected from unauthorized parties. Only  subject initials, date of birth, another 
unique identifier (as allowed b y local law) and an identification code will be recorded on an y 
form or biological sample submitted to the Sponsor, IRB/IEC,or laboratory . Laboratory  
specimens must be labeled in such a way as to protect subject identity  while allowing the results 
to be recorded to the proper subject. Refer to specific laboratory  instructions or in accordance 
with local regulations. NOTE : The investigator must keep a screening log showing codes, names, 
and addresses for all subjects screened and for all subjects enrolled in the trial. Subject data will 
be processed in accordance with all applicable regulations.
The investigator agrees that all information received from [COMPANY_009], including but not limited to the 
investigator brochure, this protocol, CRF /eCRF , the study  drug , and any  other study  information, 
remain the sole and exclusive propert y of [COMPANY_009] during the conduct of the study and t hereafter. 
This information is not to be disclosed to an y third party (except emplo yees or agents directly  
involved in the conduct of the study  or as required by  [CONTACT_2371]) without prior written consent from 
[COMPANY_009]. The investigator further agrees to take all re asonable precautions to prevent the 
disclosure b y any employee or agent of the stud y site to any  third party  or otherwise into the 
public domain.
9.1.5. Study Files and Retention of Records
The investigator must maintain adequate and accurate records to enable th e conduct of the stud y 
to be fully  documented and the study data to be subsequently  verified. These documents should 
be classified into at least the following two categories: (1) investigator’s study  file, and 
(2)subject clinical source documents.
The investigator’s stud y file will contain the protocol/amendments, CRF and query  forms, 
IRB/IEC, and governmental approval with correspondence, informed consent, drug records, staff 
curriculum vitae and authorization forms, and other appropriate documents and co rrespondence.
The required source data should include sequential notes containing at least the following 
information for each subject:
Subject identification (name, date of birth, gender);
Documentation that subject meets eligibility  criteria, [ie, history , phy sical examination, and 
confirmation of diagnosis (to support inclusion and exclusion criteria) ];
[COMPANY_003]
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 60 22 November 2016Documentation of the reason(s) a consented subject is not enrolled ;
Participation in study  (including study  number);
Study  discussed and date of informed consent;
Dates of all visits;
Documentation that protocol specific procedures were performed;
Results of efficacy  parameters, as required b y the protocol;
Start and end date (including dose regimen) of study  drug , including dates of dispensing and 
return;
Record of all adverse events and other safety  parameters (start and end date, and including 
causality  and severity );
Concomitant medication (including start and end date, dose if relevant; dose changes);
Date of study  completion and reason for earl y discon tinuation, if it occurs .
All clinical study  documents must be retained b y the investigator until at least [ADDRESS_238124] approval of a marketing application in 
an ICH region ( ie, [LOCATION_002], Europe, or Japan) and until there are no pending or planned 
marketing applications in an I CH region; or, if no application is filed or if the application is not 
approved for such indication, until [ADDRESS_238125] visit to enable the sponsor to perform central monitoring of 
safet y data.  The Eligibility  Criteria eCRF should be completed onl y after all data relate d to 
SOF/VEL
Protocol GS -US-342-[ADDRESS_238126] been received.  Subsequent to data entry , a study  monitor will perform source 
data verification within the EDC system. Original entries as well as any  changes to data fields 
will be stored in the audit trail of the sy stem.  Prior to database lock (or an y interim time points 
as described in the clinical data management plan), the investigator will use his/her log in 
credentials to confirm that the forms have been reviewed, and that the entries accuratel y reflect 
the information in the source documents. The eCRF capture the data required per the protocol 
schedule of events and procedures. System -generated or manual queries will be issued to the 
investigative site staff as data discrepancies are identified by  [CONTACT_199622], 
who routinely  review the data for completeness, correctness, and consistency . The site 
coordinator is responsible for responding to the queries in a timel y manner, within the system, 
either b y confirming the data as correct or updating the orig inal entry , and providing the reason 
for the update (eg, data entry  error). At the conclusion of the trial, [COMPANY_009] will provide the site 
with a read -only archive copy  of the data entered by  [CONTACT_10867]. This archive must be stored in 
accordance with the re cords retention requirements outlined in Section 9.1.[ADDRESS_238127] for drug destruction, arrangements will be made between the site and [COMPANY_009] 
Sciences (or [COMPANY_009] Sciences’ representative) for returned or unused stud y drug supplies. The 
study  monitor will provide instructions for return.  
The study  monitor will evaluate each study  center’s st udy drug disposal procedures and provide 
appropriate instruction for destruction of unused study  drug supplies. If the site has an 
appropriate standard operating procedure (SOP) for drug destruction as determined by  [CONTACT_199623], the site may  destro y used (em pty or partially empty) and unused study drug supplies in 
accordance with that site’s approved SOP. A cop y of the site’s approved SOP will be obtained 
for central files. 
If study  drug is destro yed on site, the investigator must maintain accurate records for all study  
drug destroy ed. Records must show the identification and quantity  of each unit destroy ed, the 
method of destruction, and the person who disposed of the study  drug . Upon stu dy completion, 
copi[INVESTIGATOR_199602]. Another copy  will be 
returned to [COMPANY_009]. Refer to the Pharmacy  Binder for study  drug disposal/return.
The study  monitor will review study  drug supplies and associated records at periodic intervals.
9.1.8. Inspections
The investigator will make available all source documents and other records 
for this trial to 
[COMPANY_009]’s appointed stud y monitors , to IRB/IEC , or to regulatory  authorit y or health authorit y 
inspectors.
SOF/VEL
Protocol GS -US-342-[ADDRESS_238128] submit a ll protocol modifications to the IRB/IEC in 
accordance with local requirements and receive documented IRB/ IEC approval before 
modifications can be implemented.
9.2.2. Study Report and Publications
A clinical study  report (CSR) will be prepared and provided to the regulatory agenc y(ies). [COMPANY_009] 
will ensure that the report meets the standards set out in the I CH Guideline for Structure and 
Content of Clinical Study Reports ( ICHE3). Note that an abbreviated report may  be prepared in 
certain cases.
Investigators in this study  may  communicate, orally  present, or publish in scientific journals or 
other scholarl y media only after the following conditions have been met:
the resul ts of the study  in their entiret y have been publicly disclosed b y or with the consent of 
[COMPANY_009] in an abstract, manuscript, or presentation form or the stud y has been completed at all 
study  sites for at least [ADDRESS_238129] 30 day s before submission of the 
publication or presentation. 
No such communication, presentation, or publication will include [COMPANY_009]’s c onfidential 
information (see Section 9.1.4).
The investigator will comply  with [COMPANY_009]’s request to delete references to its confidential 
information (other than the study  results) in any  paper or presentation and agrees to withhold 
publication or presentation for an additional 60 days in order to obtain patent protection if 
deemed necessary .
9.3. Joint Investigator/Sponsor Responsibilities
9.3.1. Payment Reporting
Investigators and their study  staff may  be asked to provide services performed under this 
protocol, eg ,attendance at I nvestigator's Meetings.  If required under the applicable statutory  and 
regulatory  requirements, [COMPANY_009] will capture and disclose to Federal and State agencies any  
SOF/VEL
Protocol GS -US-342-[ADDRESS_238130] access to the 
investigator’s source documentation in order to verify  the accuracy  of the data recorded in the 
CRF /eCRF .
The monitor is responsible for routine review of the CRF /eCRF at regular intervals throughout 
the study  to verify  adherence to the protocol and the completeness, consistenc y, and accuracy  of 
the data being entered on them. The monitor should have access to an y subject records needed to 
verify  the entries on the CRF /eCRF . The investigator agrees to cooperate with the monitor to 
ensure that an y problems detected through any  type of monitoring (central, on site) are resolved.
9.3.3. Access to Information for Auditing or Inspections
Representatives of regulatory  authorities or of [COMPANY_009] may  conduct inspections or audits of the 
clinical study . If the investigator is notified of an inspec tion by  a regulatory authority  the 
investigator agrees to notify  the [COMPANY_009] M edical Monitor immediately . The investigator agrees to 
provide to representatives of a regulatory  agency  or [COMPANY_009] access to records, facilities, and 
personnel for the effective c onduct of any  inspection or audit.
9.3.4. Study Discontinuation
Both the sponsor and the investigator reserve the right to terminate the stud y at an y time. Should 
this be necessary , both parties will arrange discontinuation procedures and notify  the appropriate 
regulatory  authorit y(ies), I RBs, and IECs. In terminating the study , [COMPANY_009] and the investigator 
will assure that adequate consideration is given to the protection of the subjects’ interests.
SOF/VEL
Protocol GS -US-342-[ADDRESS_238131], L awitz E, Gordon SC, Schiff E, et al. Ledipasvir and 
sofosbuvir for previously treated HCV genoty pe 1 infection. N Engl J Med 
2014a;370 (16):1483 -93.
Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. L edipasvir and sofosbuvir for 
untreated HCV ge notype 1 infection. N Engl J Med 2014b;370 (20):1889- 98.
Allison RD, Tong X, Moorman AC, Ly  KN, Rupp L , Xu F, et al. Increased Incidence of Cancer 
and Cancer -related Mortality  Among Persons with Chronic Hepatitis C I nfection, 
2006- 2010. J Hepatol 2015.
Arias A, Aguilera A, Soriano V, Benitez- Gutierrez L , Lledo G, Navarro D, et al. Rate and 
predictors of treatment failure to all- oral HCV regimens outside clinical trials. 
Antivir Ther 2016.
Charlton M, Everson GT, Flamm SL , Kumar P, Landis C, Brown Jr RS, et al. Ledipasvir and 
Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients with 
Advanced Liver Disease. Gastroenterology  2015:649 -
59.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 
1976;16:31-41.
Curry MP, O'Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, et al. Sofosbuvir and 
Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med 
2015.
[COMPANY_009] Sciences Inc. SOVALDI® (sofosbuvir) tablets, for oral use. US Prescribing Informatio n.  
Foster City , CA. December 2013:
[COMPANY_009] Sciences Inc. EPCL [LOCATION_003]® (sofosbuvir and velpatasvir) tablets, for oral use. US 
Prescribing Information. Foster City , CA. Revised June.  2016a:
[COMPANY_009] Sciences Inc. HARVONI® (ledipasvir and sofosbuvir) tablets, for oral use. U.S. 
Prescribing Information. Foster City , CA.  Revised June.  2016b:
[COMPANY_009] Sciences International L td. Epclusa 400 mg/100 mg film -coated tablets (SmPC).  
2016:41. 
[COMPANY_009] Sciences International Ltd. HARVONI (ledipasvir/sofosbuvir) 90 mg/[ADDRESS_238132] Characteristics. Cambridge, [LOCATION_006]. Revised 
April.  2016:
Gower E, Estes C, Blach S, Razavi- Shearer K, Razavi H. Global epi[INVESTIGATOR_199603] C virus infection. J Hepatol 2014.
Ioannou G N, Beste LA, Chang MF, Green PK, Lowey  E, Tsui J I, et al. Effectiveness of 
Sofosbuvir, L edipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and 
Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans 
Affairs National Healthcare System [Accepted Manuscript]. Gastroenterology  
2016;151:457-71.
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 65 22 November 2016Kowdley  KV, Gordon SC, Reddy  KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and 
sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 
2014;370 (20):1879-88.
Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, et al. Ledipasvir and 
sofosbuvir plus ribavirin in patients with genot ype 1 or 4 hepatitis C virus 
infection and advanced liver disease: a multicentre, open- label, randomised, phase 
[ADDRESS_238133] Dis 2016;16:685 -97.
MEL D/PELD. Calculator Documentation. 28 January .  2009:
Morgan RL , Baack B, Smith BD, Yartel A, Pi[INVESTIGATOR_199604] M, Falck -Ytter Y. Eradication of Hepatitis C 
Virus Infection and the Development of Hepatocellular Carcinoma. Ann Intern 
Med 2013;158 (5 (Part I)).
Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus 
and hepatitis C virus infections to cirrhosis and primary  liver cancer worldwide. J 
Hepatol 2006;45 (4):529-38.
Poynard T, McHutchison J, Manns M, Trepo C, L indsay  K, Goodman Z, et al. I mpact of 
pegy lated interferon alfa -2b and ribavirin on liver fibrosis in patients with chronic 
hepatitis C. Gastroenterology  2002;122 (5):1303-13.
[COMPANY_002] Laboratories Inc. COPEGUS® (ribavirin, USP) TABLETS. U S Prescribing Information. 
Nutley , NJ. Revised: January  2010.
[COMPANY_002] Products L imited. Copegus 200mg and 400mg Film -coated Tablets. Summary  of Product 
Characteristics. Welwy n Garden Cit y, [LOCATION_008]. Revised: March 2010.
van der Meer AJ, Veldt BJ, Feld JJ, Wedemey er H, Dufour JF, Lammert F, et al. Association 
between sustained virological response and all -cause mortality  among patients 
with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308 
(24):2584-93.
Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al. Sustained 
virologic response and clinical outcomes in patients with chronic hepatitis C and 
advanced fibrosis. Ann Intern Med 2007;147 (10):677-84.
World Health Organization (WHO). Hepatitis C Fact Sheet No. 164. Av ailable at: 
http://www.who.int/mediacentre/factsheets/fs164/en/#. Accessed 20 June 2014:1 -
7.
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 66 22 November 201611. APPENDICES
Appendix 1. Investigator Signature [CONTACT_10882] 2. Study Procedures Table
Appendix 3. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Appendix 4. Pregnancy Precautions, Definition for Female of Childbearing Pote ntial, and 
Contraceptive Requirements
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]SOF/VEL 
Protocol GS-US-342-[ADDRESS_238134] 
FOSTER CITY, CA [ZIP_CODE] 
STUDY ACKNOWLEDGEMENT 
A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of 
Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Subjects 
with Chronic HCV Infection and Child-Pugh- Turcotte Class C Cirrhosis 
GS-US-342-4022, Protocol Amendment 1, 22 November 2016 
This protocol has been approved by [CONTACT_10869], Inc. The following signature [CONTACT_9002] 
(Printed) 
Date 
INVESTIGATOR STATEMENT 
[have read the protocol, including all appendices , and r agree that it contains all necessary 
details for me and my staff to conduct this study as described. I will conduct this study as 
outlined herein and wiU make a reasonable effort to complete the study within the time 
designated. 
I will provide all study personnel under my supervision copi[INVESTIGATOR_199605], Inc. I will discuss this material with them to ensure 
that they are fully informed about the drugs and the study. 
Principal Investigator [CONTACT_5627] (Printed) 
Date 
CONFIDENT'lAL ' \ Signature 
[CONTACT_199626] 67 22 November 20) 6 
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 68 22 November 2016Appendix 2. Study Procedures Table
Screen Day1aOn-treatment Study Week (± 3 days) Posttreatm ent Study Week (± 5 days)
2 4 8 12/ET 4 12 24
Informed Consent X
Determine Eligibility X X
Medical History X
Physical Examination X X X X X
Assess ascites and hepatic 
encephalopathyX X X X X X X X X
Height X
Weight X X X X X X X X X
Vital SignsbX X X X X X X X X
12-Lead ECG X X
AEs X X X X X X X
Concomitant Medications X X X X X X X
Pregnancy Prevention 
CounselingX X X X X X X X
Health Related Quality of 
LifecX X X
Study Drug DispensingdX X X
Revie w of Study 
Drug Com plianceeX X X X
Hem atology, Chemistry X X X X X X X X X
Coagulation Tests X X X X X X X X X
Urinalysis X X X
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 69 22 November 2016Screen Day1aOn-treatment Study Week (± 3 days) Posttreatm ent Study Week (± 5 days)
2 4 8 12/ET 4 12 24
HCV RNA X X X X X X X X X
HBV DNAfX X X X X X X
Viral Sequencing  X X X X X X X X
Single PK X X X X
Serum β -hCG or Urine 
Pregnancy TestgX X X X X X X X
Urine Drug Screen X
HbA1c X
HCV & IL28B 
Genotypi[INVESTIGATOR_007] X
HCV, HIV, HBV 
SerologyX
Fibrotest®X
a Day [ADDRESS_238135] be performed prior to dosing .
b Vital signs include resting blood pressure, pulse, respi[INVESTIGATOR_7146].
c There are four Health Related Quality of Life surveys to provide to subjects: SF -36, CLDQ -HCV, FACIT -F, and WPAI.
d The IWRS will provide direction on the specifics of each subject’s study drug dispensing .
e Instruct the subject to bring back all study drugs and study drug containers (used/unused) .
f Only for subje cts who are HBcAb+ at Screening
[COMPANY_003]
[COMPANY_003]
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 70 22 November 2016Appendix 3. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Antiviral Toxicity Grading Scale Version: 01 April 2015
HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Hem oglobin
HIV POSITIVE
Adult and Pediatric 57 Days8.5to10.0 g/dL 
85 to 100 g/L7.5to 8.5g/dL 
75to85g/L6.5 to 7.5g/dL 
65 to 75g/L6.5g/dL
65g/L
HIV NEGATIVE
Adult and Pediatric 57 Days 10.0 to10.9 g/dL
100to109g/L
OR
Any decrease from Baseline
2.5 to 3.5g/dL
25 to 35g/L9.0 to 10.0 g/dL
90 to 100g/L
OR
Any decrease from Baseline
3.5 to 4.5g/dL
35 to 45g/L7.0 to 9.0g/dL
70 to 90g/L
OR
Any decrease from Baseline
4.5g/dL
45g/L7.0g/dL
70g/L
Infant, 36 –56 Days
(HIV POSITIVE OR
NEGATIVE )8.5 to 9.4 g/dL
85 to 94 g/L7.0 to 8.5g/dL
70 to 85g/L6.0 to 7.0 g/dL
60 to < 70 g/L6.0 g/dL
< 60 g/L
Infant, 22 –35 Days
(HIV POSITIVE OR
NEGATIVE )9.5 to 10.5 g/dL
95 to 105 g/L8.0 to 9.5g/dL
80 to 95g/L7.0 to 8.0g/dL
70 to 80g/L7.0g/dL
70g/L
Infant, 1–21 Days
(HIV POSITIVE OR
NEGATIVE )12.0 to 13.0 g/dL
120 to 130 g/L10.0 to 12.0 g/dL
100 to 120g/L9.0 to 10.0 g/dL
90 to 100g/L9.0g/dL
90g/L
Absolute Neutrophil Count  
(ANC)
Adult and Pediatric, 
≥ 7 Months# 1000 to1300/mm3750to1000/mm3500to750/mm3500/mm3
1.00 to 1.30 GI/L 0.75 to 1.00 GI/L 0.50 to0.75 GI/L 0.50 GI/L
Absolute CD4+ Count
HIV NEGATIVE ONLY
Adult and Pediatric 
>13Years300to400/mm3
300to400/μL200to300/mm3
200to 300/μL100to200/mm3
100to200/μL100/mm3
100/μL
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 71 22 November 2016HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Absolute Lymphocyte Count
HIV NEGATIVE ONLY
Adult and Pediatric 
13Years600 to 650/mm3
0.60 to 0.65 GI/L500 to 600/mm3
0.50 to 0.60 GI/L350 to 500/mm3
0.35 to 0.50 GI/L350/mm3
0.35 GI/L
Platelets 100,000 to < 125,000/mm3
100to125 GI/L50,000 to 100,000/mm3
50to 100 GI/L25,000 to 50,000/mm3
25 to 50 GI/L25,000/mm3
25GI/L
WBCs 2000/mm3to 2500/mm31,500 to  2,000/mm31000 to 1,500/mm31000/mm3
2.00 GI/L to 2.50 GI/L 1.50 to 2.00 GI/L 1.00 to 1.50 GI/L 1.00 GI/L
Hypofibrinogenemia 100to200mg/dL 75 to 100mg/dL 50to 75mg/d L 50mg/d L
1.00 to2.00 g/L 0.75 to 1.00 g/L 0.50 to 0.75 g/L 0.50 g/L
Hyperfibrinogenemia ULN to 600 mg/dL 600mg/dL — —
ULN  to 6.0 g/L 6.0g/L — —
Fibrin Split Product 20 to 40 μg/mL 40to 50μg/mL 50to 60μg/mL 60μg/mL
20 to 40 mg/L 40 to 50 mg/L 50 to 60 mg/L 60mg/L
Prothrombin Time (PT) 1.00 to 1.25 ULN 1.25 to 1.50 ULN 1.50 to 3.00 ULN 3.00 ULN 
International Normalized Ratio 
of prothrombin time (INR)1.[ADDRESS_238136] >1.[ADDRESS_238137] >2.[ADDRESS_238138] >3.[ADDRESS_238139]
Activated Partial
Thromboplastin Time (APTT) 1.00 to 1.66ULN 1.66 to 2.33ULN 2.33 to 3.00ULN 3.00 ULN
Methemoglobin 5.0to10.0% 10.0 to15.0% 15.0 to20.0% 20.0% 
# An overlap between the Grade 1 scale and the Lab’s normal range for absolute neutrophils may result for pediatric subjects.  Please follow the [COMPANY_009] convention of grading 
any result within the LLN and ULN a 0.  
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 72 22 November 2016CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hyponatremia 130 to <LLN mEq/L 125 to130mEq/L 121 to125mEq/L 121 mEq/L
130 to <LLN mmol/L 125 to130mmol/L 121 to125mmol/L 121 mmol/L
Hypernatremia >ULN  to 150 mEq/L 150 to 154 mEq/L 154 to 159 mEq/L 159 mEq/L
>ULN  to 150 mmol/L 150 to 154 mmol/L 154 to 159 mmol/L 159 mmol/L
Hypokalemia
Adult and Pediatric
1 Year3.0 to  <LLN mEq/L 2.5 to3.0mEq/L 2.0 to2.5mEq/L 2.0 mEq/L
3.0 to <LLN mmol/L 2.5 to3.0mmol/L 2.0 to2.5mmol/L 2.0 mmol/L
Infant  <1 Year 3.0 to 3.4 mEq/L
3.0 to 3.4 mmol/L2.5 to3.0mEq/L
2.5 to <3.0 mmol /L2.0 to2.5mEq/L
2.0 to<2.5 mmol /L2.0 mEq/L 
<2.0 mmol /L
Hyperkalemia
Adult and Pediatric
1 Year5.6 to 6.0 mEq/L
5.6 to 6.0 mmol/L6.0 to 6.5 mEq/L
6.0 to 6.5 mmol/L6.5 to 7.0 mEq/L
6.5 to 7.0 mmol/L7.0 mEq/L
7.0 mmol/L
Infant  <1 Year >ULN to 6.0 mEq/L
>ULN to 6.0 mmol/L> 6.0 to 6.5 mEq/L
> 6.0 to 6.5 mmol/L6.5 to 7.0 mEq/L
6.5 to 7.0 mmol/L7.0 mEq/L
7.0 mmol/L
Hypoglycemia
Adult and Pediatric
1Month55 to 64 mg/dL
3.03 to 3.58 mmol/L40 to55mg/d L
2.20 to3.03 mmol/L30 to40mg/d L
1.64 to2.20 mmol/L30 mg/dL
1.64 mmol/L
Infant,1Month 50 to 54 mg/dL
2.8 to 3.0 mmol/L40 to 50mg/d L
2.2 to 2.8mmol/L30 to 40mg/d L
1.7 to 2.2mmol/L30 mg/dL
1.7 mmol/L
Hyperglycemia, Nonfasting 116to 160 mg/dL 160 to 250 mg/dL 250 to 500 mg/dL 500 mg/dL
6.42 to 8.91 mmol/L 8.91 to 13.90 mmol/L 13.90 to 27.79 mmol/L 27.79 mmol/L
Hyperglycemia, Fasting 110 to 125 mg/dL
6.08 to 6.96 mmol/L>125 to 250 mg/dL
>6.96 to 13.90 mmol/L>250 to 500 mg/dL
>13.90 to 27.79 mmol/L>500 mg/dL
>27.79 mmol/L
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 73 22 November 2016CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hypocalcemia
(corrected for albumin if 
appropriate*)
Adult and Pediatric
2 Years7.8 <LLN mg/dL
1.94 to <LLN mmol/L7.0 to7.8 mg/dL
1.74 to1.94 mmol/L6.1 to7.0mg/dL
1.51 to1.74 mmol/L6.1mg/d L
1.51 mmol/L
Pediatric ≥7 days -2 Years 7.8 to 8.4 mg/dL
1.94 to 2.10 mmol/L7.0 to <7.8 mg/dL
1.74 to <1.94 mmol /L6.1 to  <7.0 mg/dL
1.51 to < 1.74 mmol/L< 6.1 mg/dL
< 1.51 mmol/L
Infant,7Days 6.5 to 7.5 mg/dL
1.61 to 1.88  mmol/L6.0 to 6.5 mg/dL
1.49 to < 1.61 mmol/L5.5 to 6.0 mg/dL
1.36 to < 1.49 mmol/L 5.5 mg/dL
< 1.36 mmol/L
Hypercalcemia (corrected 
for albumin if appropriate*)
Adult and Pediatric 
7Days>ULN to 11.5 mg/dL 11.5 to 12.5 mg/dL 12.5 to 13.5 mg/dL 13.5 mg/dL
>ULN to 2.88 mmol/L 2.88 to 3.13 mmol/L 3.13 to 3.38 mmol/L 3.38 mmol/L
Infant,7Days 11.5 to 12.4 mg/dL
2.86 to 3.10  mmol/L12.4 to 12.9 mg/dL
> 3.10 to 3.23  mmol/L12.9 to 13.5 mg/dL
> 3.23 to 3.38  mmol/L13.5 mg/dL
> 3.38 mmol/L
Hypocalcemia (ionized) 3.0 mg/dL to LLN 2.5 to < 3.0 mg/dL 2.0 to2.5 mg/dL 2.0 mg/dL
0.74 mmol/L to LLN 0.62 to0.74 mmol/L 0.49 to0.62 mmol/L 0.49 mmol/L
Hypercalcemia (ionized) ULN to 6.0 mg/dL 6.0 to 6.5 mg/dL 6.5 to 7.0 mg/dL 7.0 mg/dL
ULN to 1.50 mmol/L 1.50 to 1.63 mmol/L 1.63 to 1.75 mmol/L 1.75 mmol/L
Hypomagnesemia 1.40 to  <LLN mg/dL
1.2 to <LLN mEq/L1.04 to1.40 mg/dL
0.9 to   1.2 mEq/L0.67 to1.04 mg/dL
0.6 to 0.9 mEq/L0.67 mg/dL
0.6 mEq/L
0.58 to <LLN mmol/L 0.43 to0.58 mmol/L 0.28 to0.43 mmol/L 0.28 mmol/L
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 74 22 November 2016CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hypophosphatemia
Adult and Pediatric
14Years2.0 to < LLN mg/dL
0.63  to LLN mmol/L1.5 to 2.0 mg/dL
0.47 to 0.63 mmol/L1.0 to 1.5 mg/dL
0.31 to 0.47 mmol/L1.0 mg/dL
0.31 mmol/L
Pediatric 1 Year– 14 Years 3.0 to <LLN mg/dL
0.96 to <LLN mmol/L2.5 to 3.0 mg/dL
0.80 to < 0.96 mmol/L1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L1.5 mg/dL
<0.47 mmol/L
Pediatric 1Year 3.5 to <LLN mg/dL
1.12 to <LLN mmol/L2.5 to 3.5mg/dL
0.80 to < 1.12 mmol/L1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L1.5 mg/dL
<0.47 mmol/L
Hyperbilirubinemia
Adult and Pediatric 
>14Days1.0 to 1.5 ULN 1.5 to 2.5 ULN 2.5 to 5.0 ULN 5.0 ULN 
Infant, 14Days
(non-hemolytic)NA 20.0 to 25.0 mg/dL
342 to 428 μmol/L25.0 to 30.0 mg/dL
> 428 to 513 μmol/L30.0 mg/dL
> 513 μmol/L
Infant, 14Days
(hemolytic)NA NA 20.0 to 25.0 mg/dL
342 to 428 μmol/L25.0 mg/dL
> 428 μmol/L
Blood Urea Nitrogen 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
Hyperuricemia >ULN to 10.0 mg/dL 10.0 to 12.0 mg/dL 12.0 to 15.0 mg/dL 15.0 mg/dL
>ULN to 597 μmol/L 597 to 716 μmol/L 716 to 895 μmol/L 895 μmol/L
Hypouricemia
Adult and Pediatric
≥ 1 year
Infant  < 1 Year1.5 mg/dL to LLN
87 μmol/L to LLN1.0 to1.5 mg/dL
57 to87 μmol/L0.5 to1.0 mg/dL
27 to57 μmol/L0.5 mg/dL
27 μmol/L
N/A 1.0 mg/dl to <LLN -
57 μmol to <LLN0.5 to1.0 mg/dL
27 to57 μmol/L0.5 mg/dL
27 μmol/L
Creatinine** 1.50 to 2.00 mg/dL
133 to 177 μmol/L2.00 to 3.00 mg/dL
177 to 265 μmol/L3.00 to 6.00 mg/dL
265 to 530 μmol/L6.00 mg/dL
530 μmol/L
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 75 22 November 2016CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Bicarbonate
Adult and Pediatric
≥ 4 Years16.0 mEq/L to LLN 11.0 to16.0 mEq/L 8.0 to11.0 mEq/L 8.0 mEq/L
16.0 mmol/L to LLN 11.0 to16.0 mmol/L 8.0 to11.0 mmol/L 8.0 mmol/L
Pediatric < 4 Years NA 11.0 mEq/Lto <LLN 8.0 to11.0 mEq/L 8.0 mEq/L
11.0 mmol/L to <LLN 8.0 to11.0 mmol/L 8.0 mmol/L
Triglycerides
(Fasting)NA 500 to 750 mg/dL
5.64–8.47 mmol/L750 to 1200 mg/dL
8.47–13.55 mmol/L1200 mg/dL
13.55 mmol/L
LDL (Fasting)
Adult130 to 160 mg/dL >160 to 190 mg/dL > 190 mg/dL NA
3.35 to 4.15 mmol/L >4.15 to 4.92 mmol/L >4.92 mmol/L
LDL (Fasting)
Pediatric >2 to <18 years110 to 130 mg/dL >130 to 190 mg/dL > 190 mg/d L NA
2.84 to 3.37 mmol/L >3.37 to  4.92 mmol/L >4.92 mmol/L
Hypercholesterolemia
(Fasting)200 to 239 mg/dL 239 to 300 mg/dL 300 mg/dL NA
5.16 to 6.19 mmol/L 6.19 to 7.77 mmol/L 7.77 mmol/L
Pediatric 18 Years 170 to 199 mg/dL
4.39 to 5.15 mmol/L199 to 300 mg/dL
5.15 to 7.77 mmol/L300 mg/dL
7.77 mmol/LNA
Creatine Kinase 3.0 to6.0 ULN 6.0 to10.0 ULN 10.0 to20.0 ULN 20.0 ULN
* Calcium should be corrected for albumin if albumin is < 4.0 g/dL
** An overlap between the Grade 1 scale and the Lab’s normal range for creatinine may result for Male subjects >[ADDRESS_238140] a 0.  
SOF/VEL
Protocol GS -US-342-[ADDRESS_238141] (SGOT) 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
ALT (SGPT) 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
GGT 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
Alkaline Phosphatase 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00  ULN
Total Amylase 1.0 to 1.5 ULN 1.5 to 2.0 ULN 2.0 to 5.0 ULN 5.0 ULN
Pancreatic Amylase 1.0 to 1.5 ULN 1.5 to 2.0 ULN 2.0 to 5.0 ULN 5.0 ULN
Lipase 1.0 to 1.5 ULN 1.5 to 3.0 ULN 3.0 to 5.0 ULN 5.0 ULN
Albumin
Pediatrics <16 years 
≥ 16 years- 2.0 to LLN g/dL
20 to LLN g/L2.0 g/dL
20 g/LNA
3.0 g/dL to LLN
30 g/L to LLN2.0 to 3.0 g/dL
20 to 30 g/L2.0 g/dL
20 g/LNA
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 77 22 November 2016URINALYSIS
Grade 1 Grade 2 Grade 3 Grade 4
Hem aturia (Dipstick) 1 2 3-4+ NA
Hem aturia (Quantitative) 
See Note below
                              Females >ULN -10RBC/HPF 10-75RBC/HPF > 75 RBC/HPF NA
                              Males 6-10 RBC/HPF 10-75RBC/HPF > 75 RBC/HPF NA
Proteinuria (Dipstick) 1 2–3 4 NA
Proteinuria, 24 Hour Collection
Adult and Pediatric 
10 Years200 to999 mg/24 h >999 to 1999 mg/24 h >1999 to3500 mg/24 h 3500 mg/24 h
Pediatric 3 Mo to 
<10Years201 to499 mg/m2/24h >499 to799 mg/m2/24 h >799 to1000 mg/m2/24 h 1000 mg/ m2/24 h
Glycosuria (Dipstick) 1+ 2-3 4 NA
Notes: 
 Toxicity grades for Quantitative and Dipstick Hematuria will be assigned by [CONTACT_10870], however for other laboratories, toxicity grades will only be assigned to 
Dipstick Hematuria.
 With the exception of lipid tests, any graded laboratory test with a result that is between the LLN and ULN should be assigne d Grade 0.
 If the severity of a clinical AE could fall under either one of two grades (eg, the severity of an AE could be either Grade 2 or Grade 3), select the higher of the two grades for 
the AE.
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 78 22 November 2016CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Cardiac Arrhythmia (general)
(By [CONTACT_10871])Asymptomatic AND No 
intervention indicatedAsymptomatic AND Non -
urgent medical intervention 
indicatedSymptomatic, non -life-
threatening AND Non -
urgent medical intervention 
indicated Life-threatening arrhythmi a 
OR Urgent intervention 
indicated
Cardiac- ischemia/Infarction NA NA Symptomatic ischemia 
(stable angina) OR Testing 
consistent with ischemia Unstable angina OR Acute 
myocardial infarction
Hem orrhage (significant acute 
blood loss)NA Symptomatic AND No 
transfusion indicatedSymptomatic AND 
Transfusion of 2units 
packed RBCs (for children 
10cc/kg) indicated Life-threatening hypotension 
OR Transfusion of 2units 
packed RBCs indicated (for 
children 10cc/kg) indicated
Hypertension (with repeat 
testing at same visit)140–159mmH g systolic 
OR 
90–99 mmHg diastolic159–179 mmHg systolic
OR
99–109 mmHg diastolic179mmHg systolic 
OR 
109mmHg diastolicLife-threatening consequences 
(eg,malignant hypertension) 
OR Hospi[INVESTIGATOR_059] (other than 
ER visit) indicated
Pediatric 17Years (with 
repeat testing at same visit)NA 91st–94th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)≥95th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)Life-threatening consequences 
(eg,malignant hypertension) 
OR Hospi[INVESTIGATOR_374] 
(other than emergency room 
visit)
Hypotension NA Symptomatic, corrected w ith 
oral fluid replacementSymptomatic, IV fluids 
indicatedShock requiring use of 
vasopressors or mechanical 
assistance to maintain blood 
pressure
Pericardial Effusion Asymptomatic, small 
effusion requiring no 
interventionAsymptomatic, moderate or 
larger effusion requiring no 
interventionEffusion with non -life-
threatening physiologic 
consequences OR Effusion 
with nonurgent intervention 
indicatedLife-threatening consequences 
(eg,tamponade) OR Urgent 
intervention indicated
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 79 22 November 2016CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Prolonged PR Interval PR interval 
0.21 to 0.25 secPR interval
0.25 secType II 2nd degree AV 
block OR Ventricular pause 
3.0 secCom plete AV block 
Pediatric [ADDRESS_238142] degree AV block
(PR > normal for age and 
rate)Type I 2nd degree AV block Type II 2nd degree AV 
block Com plete AV block
Prolonged QTc Asymptomatic, QTc interval 
0.45 to 0.47 sec OR Increase 
interval 0.03 sec above 
baselineAsymptomatic, QTc interval 
0.48 to 0.49 sec OR Increase 
in interval 0.03 to 0.05 sec 
above baselineAsymptomatic, QTc interval 
0.50 sec OR Increase in 
interval 0.06sec above 
baselineLife-threatening 
consequences, eg,Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Pediatric 16Years Asymptomatic, QTc interval 
0.450 to 0.464 sec Asymptomatic, QTc interval 
0.465 to 0.479 sec Asymptomatic, QTc interval 
0.480 sec Life-threatening 
consequences, eg,Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Thrombosis/Embolism NA Deep vein thrombosis AND 
No intervention indicated ( eg,
anticoagulation, lysis filter, 
invasive procedure) Deep vein thrombosis AND 
Intervention indicated ( eg,
anticoagulation, lysis filter, 
invasive procedure) Embolic event ( eg,pulmonary 
embolism, life -threatening 
thrombus) 
Vasovagal Epi[INVESTIGATOR_1865] (associated 
with a procedure of any kind)Present without loss of 
consciousness Present with transient loss of 
consciousnessNA NA
Ventricular Dysfunction 
(congestive heart failure, 
CHF)NA Asymptomatic diagnostic 
finding AND intervention 
indicatedNew  onset with s ymptoms 
OR Worsening symptomatic 
CHFLife-threatening CHF
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 80 22 November 2016RESPI[INVESTIGATOR_10806] 1 Grade 2 Grade 3 Grade 4
Bronchospasm (acute) FEV1 or peak flow  reduced to 
70% to 80%FEV1 or peak flow  50% to 69% FEV1 or peak flow  25% to 
49% Cyanosis OR FEV1 or peak flow  
25% OR Intubation
Dyspnea or Respi[INVESTIGATOR_10807] & functional 
activities Dyspnea on exertion causing 
greater than minimal interference 
with usual social & functional 
activities Dyspnea at rest causing 
inability to perform usual 
social & functional activities Respi[INVESTIGATOR_10808] 14 Years Wheezing OR minimal 
increase in respi[INVESTIGATOR_10809] 
90% to 95%Dyspnea at rest causing 
inability to perform usual 
social & functional activities 
OR Pulse oximetry 90%Respi[INVESTIGATOR_696] f ailure with 
ventilatory support indicated
OCULAR/VISUAL
Grade 1 Grade 2 Grade 3 Grade 4
Uveitis Asymptomatic but detectable 
on examSymptomatic anterior uveitis OR 
Medical intervention indicatedPosterior or pan -uveitis OR 
Operative intervention 
indicatedDisabling visual loss in affected 
eye(s) 
Visual Changes (from 
baseline)Visual changes causing no or 
minimal interference with 
usual social & functional 
activitiesVisual changes causing greater 
than minimal interference with 
usual social & functional 
activitiesVisual changes causing 
inability to perform usual 
social & functional activitiesDisabling visual loss in affected 
eye(s)
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 81 22 November 2016SKIN
Grade 1 Grade 2 Grade 3 Grade 4
Alopecia Thinning detectable by 
[CONTACT_10872] (for disabled 
adults)Thinning or patchy hair loss 
detectable by [CONTACT_110106] –Rash Localized macular rash Diffuse macular, 
maculopapular, or 
morbilliform rash OR Target 
lesions Diffuse macular, 
maculopapular, or morbilliform 
rash with vesicles or limited 
number of bullae OR 
Superficial ulcerations of 
mucous membrane limited to 
one siteExtensive or generalized 
bullous lesions OR 
Stevens -Johnson syndrome 
OR Ulceration of mucous 
membrane involving two 
or more distinct mucosal 
sites OR Toxic epi[INVESTIGATOR_7387] (TEN)
Hyperpi[INVESTIGATOR_199606] (itching –no skin 
lesions) 
(See also Injection Site 
Reactions: Pruritus associated 
with injection)Itching causing no or 
minimal interference with 
usual social & functional 
activitiesItching causing greater than 
minimal interference with 
usual social & functional 
activitiesItching causing inability to 
perform usual social & 
functional activities NA
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 82 22 November 2016GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Anorexia Loss of appetite w ithout 
decreased oral intakeLoss of appetite associated with 
decreased oral intake without 
significant weight loss Loss of appetite associated 
with significant weight loss Life-threatening consequences 
OR Aggressive intervention 
indicated [ eg,tube feeding or 
total parenteral nutri tion]
Ascites Asymptomatic Symptomatic AND Intervention 
indicated ( eg,diuretics or 
therapeutic paracentesis)Symptomatic despi[INVESTIGATOR_10811]-threatening consequences
Cholecystitis NA Symptomatic AND Medical 
intervention indicatedRadiologic, endoscopic, or 
operative intervention 
indicatedLife-threatening consequences 
(eg,sepsis or perforation) 
Constipation NA Persistent constipation requiring 
regular use of dietary 
modifications, laxatives, or 
enemas Obstipation with manual 
evacuation indicatedLife-threatening consequences 
(eg,obstruction)
Diarrhea
Adult and Pediatric 
1YearTransient or intermittent 
epi[INVESTIGATOR_10812] 3stools 
over baseline/24 hr.Persistent epi[INVESTIGATOR_10813] 
4–6 stools over baseline per 
24hrs. Bloody diarrhea OR Increase 
of 7stools per 24 -hour 
period OR IV fluid 
replacement indicatedLife-threatening consequences 
(eg,hypotensive shock)
Pediatric 1Year Liquid stools (more 
unformed than usual) but 
usual number of stoolsLiquid stools with increased 
number of stools OR Mild 
dehydrationLiquid stools with moderate 
dehydrationLiquid stools resulting in 
severe dehydration with 
aggressive r ehydration 
indicated OR Hypotensive 
shock
Dysphagia -Odynophagia Symptomatic but able to eat 
usual dietSymptoms causing altered 
dietary intake without medical 
intervention indicatedSymptoms causing severely 
altered dietary intake with 
medical intervention indicatedLife-threatening reduction in 
oral intake
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 83 22 November 2016GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Mucositis/Stomatitis 
(clinical exam)
See also Proctitis, 
Dysphagia -OdynophagiaErythema of the mucosa Patchy pseudomembranes or 
ulcerations Confluent pseudomembranes 
or ulcerations OR Mucosal 
bleeding with minor traumaTissue necrosis OR Diffuse 
spontaneous mucosal bleeding 
OR Life -threatening 
consequences ( eg,aspi[INVESTIGATOR_1516], 
choking)
Nausea Transient ( 24hours) or 
intermittent nausea with no 
or minimal interference with 
oral intakePersistent nausea resulting in 
decreased oral intake for 24 –48 
hoursPersistent nausea resulting in 
minimal oral intake for  48 
hours OR Aggressive 
rehydration indicated ( eg,
IVfluids)Life-threatening consequences 
(eg,hypotensive shock)
Pancreatitis NA Symptomatic AND 
Hospi[INVESTIGATOR_10814] 
(other than ER visit)Symptomatic AND 
Hospi[INVESTIGATOR_374] 
(other than ER visit)Life-threatening consequences 
(eg,sepsis, circulatory failure, 
hemorrhage)
Proctitis (functional -
symptomatic)
Also see Mucositis/ 
Stomatitis for Clinical 
ExamRectal discomfort AND No 
intervention indicatedSymptoms causing greater than 
minimal interference with usual 
social & functional activities OR 
Medical intervention indicated Symptoms causing inability to 
perform usual social/ 
functional activities OR 
Operative intervention 
indicated Life-threatening consequences 
(eg,perforation)
Vom iting Transient or intermittent 
vomiting with no or 
minimal interference with 
oral intakeFrequent epi[INVESTIGATOR_10815]-threatening consequences 
(eg,hypotensive shock)
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 84 22 November 2016NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Alteration in Personality -
Behavior or in Mood ( eg,
agitation, anxiety, 
depression, mania, 
psychosis)Alteration causing no or 
minimal interference with 
usual social & functional 
activities Alteration causing greater than 
minimal interference with 
usual so cial & functional 
activities Alteration causing inability to 
perform usual social & 
functional activities Behavior potentially harmful 
to self or others ( eg,
suicidal/homicidal ideation or 
attempt, acute psychosis) OR 
Causing inability to perform 
basic s elf-care functions
Altered Mental Status 
For Dementia, see Cognitive 
and Behavioral/Attentional 
Disturbance (including 
dementia and ADD)Changes causing no or 
minimal interference with 
usual social & functional 
activitiesMild lethargy or somnolence 
causing greater than minimal 
interference with usual social 
& functional activitiesConfusion, memory 
impairm ent, lethargy, or 
somnolence causing inability 
to perform usual social & 
functional activitiesDelirium OR obtundation, OR 
coma
Ataxia Asymptomatic ataxia 
detectable on exam OR 
Minimal ataxia causing no 
or minimal interference with 
usual social & functional 
activitiesSymptomatic ataxia causing 
greater than minimal 
interference with usual social 
& functional activitiesSymptomatic ataxia causing 
inability to perform usual 
social & functional activities Disabling ataxia causing 
inability to perform basic self -
care functions
Cognitive and 
Behavioral/Attentional 
Disturbance (including 
dementia and Attention 
Deficit Disorder) Disability cau sing no or 
minimal interference with 
usual social & functional 
activities OR Specialized 
resources not indicatedDisability causing greater than 
minimal interference with 
usual social & functional 
activities OR Specialized 
resources on part -time basis 
indicatedDisability causing inability to 
perform usual social & 
functional activities OR 
Specialized resources on a 
full-time basis indicatedDisability causing inability to 
perform basic self -care 
functions OR 
Institutionalization indicated
CNS Ischemia
(acute)NA NA Transient ischemic attack Cerebral vascular accident 
(CVA, stroke) with 
neurological deficit 
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 85 22 November 2016NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Developmental delay –
Pediatric 16 YearsMild developmental delay, 
either motor or cognitive, as 
determined by [CONTACT_7424] a developmental 
screening tool appropriate 
for the setting Moderate developmental 
delay, either motor or 
cognitive, as determined by 
[CONTACT_7425] a 
developmental screening tool 
appropriate for the setting Severe developmental delay, 
either motor or cognitive, as 
determined by [CONTACT_7424] a developmental 
screening tool appropriate for 
the setting Developmental regression, 
either motor or cognitive, as 
determined b y comparison 
with a developmental 
screening tool appropriate for 
the setting
Headache Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater 
than minimal interference with 
usual social & functional 
activitiesSymptoms causing inability to 
perform usual social & 
functional activitiesSymptoms causing inability to 
perform basic self -care 
functions OR Hospi[INVESTIGATOR_373] (other than ER visit) 
OR Headache with significant 
impairm ent of alertness or
other neurologic function 
Insomnia NA Difficulty sleepi[INVESTIGATOR_10816]/functional activitiesDifficulty sleepi[INVESTIGATOR_10817] & functional activitiesDisabling insomnia causing 
inability to perform basic self -
care functions
Neuromuscular Weakness 
(including myopathy & 
neuropathy) Asymptomatic with 
decreased strength on exam 
OR Minimal muscle weak -
ness causing no or minimal 
interference with usual 
social & functional activitiesMuscle weakness causing 
greater than minimal 
interference with usual social 
& functional activitiesMuscle weakness causing 
inability to perform usual 
social & functional activities Disabling muscle weakness 
causing inability to perform 
basic self -care f unctions OR 
Respi[INVESTIGATOR_10818] 
(including paresthesia and 
painful neuropathy)Asymptomatic with sensory 
alteration on exam or 
minimal paresthesia causing 
no or minimal interference 
with usual social &
functional activities Sensory alteration or 
paresthesia causing greater 
than minimal interference with 
usual social & functional 
activities Sensory alteration or 
paresthesia causing inability to 
perform usual social & 
functional activitiesDisabling sen sory alteration or 
paresthesia causing inability to 
perform basic self -care 
functions
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 86 22 November 2016NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Seizure: (new onset) NA 1 seizure 2–4 seizures Seizures of any kind that are 
prolonged, repetitive ( eg,
status epi[INVESTIGATOR_7397]), or difficult 
to control ( eg,refractory 
epi[INVESTIGATOR_002])
Seizure: (pre- existing) 
For Worsening of Existing 
Epi[INVESTIGATOR_10819]-
existing seizures (non -
repetitive) without change in 
seizure character OR 
infrequent breakthrough 
seizures while on stable meds 
in a previously controlled 
seizure disorderChange in seizure character 
from baseline either in 
duration or quality ( eg,
severity or focality) Seizures of any kind that are 
prolonged, repetitive ( eg,
status epi[INVESTIGATOR_7397]), or difficult 
to control ( eg,refractory 
epi[INVESTIGATOR_002])
Seizure 
–Pediatric 18 YearsSeizure, generalized onset 
with or without secondary 
generalization, lasting 
< 5minutes with < 24hours 
post ictal stateSeizure, generalized onset 
with or without secondary 
generalization, lasting 5 –20 
minutes with 
< [ADDRESS_238143] ictal stateSeizure, generalized onset 
with or without secondary 
generalization, lasting 
> 20 minutes Seizure, generalized onset 
with or witho ut secondary 
generalization, requiring 
intubation and sedation
Syncope (not associated 
with a procedure)NA Present NA NA
Vertigo Vertigo causing no or 
minimal interference with 
usual social & functional 
activitiesVertigo causing greater than 
minimal interference with 
usual social & functional 
activities Vertigo causing inability to 
perform usual social & 
functional activitiesDisabling vertigo causing 
inability to perform basic self -
care functions
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 87 22 November 2016MUSCULOSKELETAL
Grade 1 Grade 2 Grade 3 Grade 4
Arthralgia
See also ArthritisJoint pain causing no or 
minimal interference with 
usual social & functional 
activitiesJoint pain causing greater than 
minimal interference with usual 
social & functional activitiesJoint pain causing inability 
to perform usual social & 
functional activitiesDisabling joint pain causing 
inability to perform basic self -
care functions
Arthritis
See also ArthralgiaStiffness or joint sw elling 
causing no or minimal 
interference with usual 
social & functional activitiesStiffness or joint sw elling causing 
greater than minimal interference 
with usual social & functional 
activitiesStiffness or joint sw elling 
causing inability to perform 
usual social & functional 
activi tiesDisabling joint stiffness or 
swelling causing inability to 
perform basic self -care 
functions
Bone Mineral Loss BMD t -score or z- score
–2.5 to –1.0 BMD t -score or z- score–2.5 Pathological fracture 
(including loss of vertebral 
height)Pathologic fracture causing 
life-threatening consequences 
Pediatric 21Years BMD z -score 
–2.5 to –1.0BMD z -score < –2.5 Pathological fracture 
(including loss of vertebral 
height)Pathologic fracture causing 
life-threatening consequences 
Myalgia
(non-injection site)Muscle pain causing no or 
minimal interference with 
usual social & functional 
activitiesMuscle pain causing greater than 
minimal interference with usual 
social & functional activitiesMuscle pain causing 
inability to perform usual 
social & functional activitiesDisabling muscle pain causing 
inability to perform basic self -
care functions
Osteonecrosis NA Asymptomatic with radiographic 
findings AND No operative 
intervention indicatedSymptomatic bone pain with 
radiographic findings OR 
Operative intervention 
indicatedDisabling bone pain with 
radiographic findings causing 
inability to perform basic self -
care functions
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 88 22 November 2016SYSTEMIC
Grade 1 Grade 2 Grade 3 Grade 4
Acute Systemic Allergic 
Reaction Localized urticaria 
(wheals) with no medical 
intervention indicatedLocalized urticaria with medical 
intervention indicated OR Mild 
angioedema with no medical 
intervention indicatedGeneralized urticaria OR 
Angioedema with medical 
intervention indicated OR 
Symptomatic mild 
bronchospasmAcute anaphylaxis OR Life -
threatening bronchospasm OR 
laryngeal edema
Chills Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activities Symptoms causing inability to 
perform usual social & 
functional activitiesNA
Fatigue
MalaiseSymptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater than 
minimal interference with usual 
social & functional activitiesSymptoms causing inability to 
perform usual social & 
functional activitiesIncapacitating fatigue/malaise 
symptoms causing inability to 
perform basic self -care 
functions
Fever (nonaxillary) 37.7C to 38.6C
99.8F to 101.5F38.7C to 39.3C
101.6F to 102.8F39.4C to 40.5C
102.9F to 104.9F40.5C
104.9F
Pain-Indicate Body Site
See also Injection Site 
Pain, Headache, 
Arthralgia, and MyalgiaPain causing no or 
minimal interference with 
usual social & functional 
activitiesPain causing greater than minimal 
interference with usual social & 
functional activitiesPain causing inability to 
perform usual social & 
functional activitiesDisabling pain causing 
inability to perform basic self -
care functions OR 
Hospi[INVESTIGATOR_059] (other than ER 
visit) indicated
Unintentional Weight 
LossNA 5% to 9% loss in body weight from 
baseline10% to 19% loss in body 
weight from baseline20% loss in body weight 
from baseline OR  Aggressive 
intervention indicated 
[eg,tube feeding or total 
parenter al nutrition]
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 89 22 November 2016INJECTION SITE REACTION
Grade 1 Grade 2 Grade 3 Grade 4
Injection Site Pain (pain 
without touching)
Or Tenderness (pain when 
area is touched) Pain/tenderness causing no 
or minimal limitation of use 
of limbPain/tenderness limiting use of 
limb OR Pain/tenderness 
causing greater than minimal 
interference with usual social 
& functional activitiesPain/tenderness causing 
inability to perform usual 
social & functional activitiesPain/tenderness causing inability 
to perform basic self -care 
function OR Hospi[INVESTIGATOR_059] 
(other than ER visit) indicated 
for management of 
pain/tenderness
Injection Site Reaction 
(Localized), 15YearsErythema OR Induration
of 55cm to 99cm (or 
2581 cm2)Erythema OR Induration OR 
Edema 9cm any diameter 
(or 81cm2)Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR DrainageNecrosis (involving dermis and 
deeper tissue)
Pediatric 15Years Erythem a OR Induration 
OR Edema present but 
2.5cm diameterErythem a OR Induration 
OR Edema > 2.5cm 
diameter but < 50% surface 
area of the extrem ity 
segment ( eg,upper 
arm/thigh)Erythem a OR Induration 
OR Edema involving 
50% surface area of the 
extremity segment 
(eg,upper arm /thigh) OR 
Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR 
DrainageNecrosis (involving dermis and 
deeper tissue)
Pruritus Associated with 
Injection 
See also Skin: Pruritus
(itching —no skin lesions)Itching localized to injection 
site AND Relieved 
spontaneously or w ith 
48h treatment Itching beyond the injection 
site but not generalized OR 
Itching localized to injection 
site requiring 48h treatment Generalized itching causing 
inability to perform usual 
social & functional activitiesNA
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 90 22 November 2016ENDOCRINE/METABOLIC
Grade1 Grade 2 Grade 3 Grade 4
Lipodystrophy ( eg,back 
of neck, breasts, 
abdomen)Detectable by [CONTACT_10874] 
(for young children and 
disabled adults)Detectable on physical exam by 
[CONTACT_110107][INVESTIGATOR_10820]-threatening consequences 
(eg,ketoacidosis, 
hyperosmolar non -ketotic 
coma) 
Gynecomastia Detectable by [CONTACT_10874] 
(for young children and 
disabled adults)Detectable on physical exam by 
[CONTACT_10876] & functional activities OR 
Thyroid suppression therapy 
indicatedSymptoms causing inability to 
perform usual social & 
functional activities OR 
Uncontrolled despi[INVESTIGATOR_10821]-threatening consequences 
(eg,thyroid storm)
Hypothyroidism Asymptomatic Symptomatic causing greater than 
minimal interference with usual 
social & functional activities OR 
Thyroid replacement therapy 
indicatedSymptoms causing inability to 
perform usual social & 
functional activities OR 
Uncontrolled despi[INVESTIGATOR_10821]-threatening consequences 
(eg,myxedema coma)
Lipoatrophy ( eg, fat loss 
from the face, extremities , 
buttocks)Detectable by [CONTACT_10874] 
(for young children and 
disabled adults)Detectable on physical exam by 
[CONTACT_199624]/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 91 22 November 2016GENITOURINARY
Grade 1 Grade 2 Grade 3 Grade 4
Intermenstrual Bleeding 
(IMB)Spotting observed by [CONTACT_110108] -
threatening hypotension OR 
Operative intervention 
indicated
Urinary Tract 
obstruction ( eg, stone)NA Signs or symptoms of urinary 
tract obstruction without 
hydronephrosis or renal 
dysfunctionSigns or symptoms of urinary 
tract obstruction with 
hydronephrosis or renal 
dysfunctionObstruction causing life -
threatening consequences
INFECTION
Grade 1 Grade 2 Grade 3 Grade 4
Infection (any other 
than HIV infection)Localized, no systemic 
antimicrobial treatment indicated 
AND Symptoms causing no or 
minimal interference with usual 
social & functional activitiesSystemic a ntimicrobial
treatment indicated OR 
Symptoms causing greater 
than minimal interference with 
usual social & functional 
activitiesSystemic antimicrobial treatment 
indicated AND Symptoms 
causing inability to perform 
usual social & functional 
activities OR Operative 
intervention (other than simple 
incision and drainage) indicatedLife-threatening 
consequences ( eg, septic 
shock)
Basic Self-care Functions: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding.
Usual Social & Functional Activities: Adaptive tasks and desirable activities, such as going to work, shoppi[INVESTIGATOR_007], cooking, use of transpo rtation, pursuing a hobby, etc.
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 92 22 November 2016Appendix 4. Pregnancy Precautions, Definition for Female of Childbearing 
Potential, and Contraceptive Requirements
1)Background
Ribavirin is contraindicated in pregnancy  as significant teratogenic and embry ocidal effects have 
been demonstrated in all animal species tested. Pregna ncy must be excluded before the start of 
treatment with study  drugs and prevented thereafter by  [CONTACT_199625]. 
Pregnancy  tests will be performed regularly  throughout this study . Furthermore, RBV is known 
to accumulate intracellularly  where it is cleared slowly , and is also excreted in semen. Therefore, 
extreme care must be taken to avoid pregnancy  during RBV therapy  and for up to [ADDRESS_238144]- menopausal, unless permanentl y sterile or with 
medically  documented ovarian failure.  
Women are considered to be in a postmenopausal state when they  are 
≥ 54 years of age with 
cessation of previously  occurring menses for ≥ [ADDRESS_238145] is considered fertile after the initiation of 
puberty  unless permanently  sterile b y bilateral orchidectomy or medical documentation.
2)Study DrugEffects on Pregnancy and Hormonal Contraception
Data from clinical pharmacokinetic interaction studies of SOF have demonstrated that there is no 
reduction in the clinical efficacy  of hormonal contraception. Non -clinical toxicity  studies of SOF 
have demonstrated no adverse effect on fertility  or embry o-fetal development .
Data from clinical pharmacokinetic interaction st udies of VEL have demonstrated that there is no 
reduction in the clinical efficacy  of hormonal contraception. Non -clinical toxicity  studies of VEL 
have demonstrated no adverse effect on fertility  or embry o-fetal development. 
However, the risks of treatmen t with SOF/VEL during pregnancy  in humans have not been 
evaluated. Please refer to the latest version of the investigator’s brochure for additional 
information.
SOF/VEL
Protocol GS -US-342-4022 Final
[COMPANY_009] Sciences, Inc. Amendment 1
CONFIDENTIAL Page 93 22 November [ZIP_CODE]) Contraception Requirements for Female Subjects of Childbearing Potential
The inclusion of female subjects of childbearing potential requires using at least an acceptable 
effective contraceptive measure. They  must have a negative serum pregnancy  test at Screening 
and a negative pregnancy test on the Day  [ADDRESS_238146] dose of SOF/ VEL  or [ADDRESS_238147].
Complete abstinence from intercourse of reproductive potential.  Abstinence is an acceptable 
method of contraception only  when it is in line with the subject’s preferred and usual 
lifesty le.
Or
Consistent and correct use of [ADDRESS_238148] dose of 
SOF/VEL or [ADDRESS_238149].
Intrauterine device (IUD) 
Intrauterine hormone -releasi ng system (IUS) 
Tubal sterilization
Essure micro- insert sy stem
Vasectom y in the male partner 
Barrier methods 
■ Female barriers: Diaphragm with spermicide or Cervical cap with spermicide
Hormonal methods
■
Oral contraceptives (either combined or progesterone only)
■Injectable progesterone
■Implants of levonorgestrel or etonogestrel
■Transdermal contraceptive patch
■Contraceptive vaginal ring
SOF/VEL
Protocol GS -US-342-[ADDRESS_238150] dose of SOF/ VEL  or [ADDRESS_238151].
4)Contraception Requirements for Male Subjects
During the study , male subjects with female partners of childbearing potential should use 
condoms until [ADDRESS_238152] dose of SOF/ VEL  or [ADDRESS_238153], when engaging in intercourse of reproductive potential. I f their female 
partner is of childbearing potential (as defined above), their female partner must use [ADDRESS_238154] dose 
of SOF/
VEL or [ADDRESS_238155] dose of
SOF/ VEL or [ADDRESS_238156].
5) Unacceptable Methods of Contraception
Birth control methods that are unacceptable include periodic abstinence (eg, calendar, ovulation, 
symptothermal, post- ovulation methods), withdrawa l (coitus interruptus), spermicides onl y, and 
lactational amenorrhea method (LAM).  Female condom and male condom should not be used 
together.
6)
Procedures to be Followed in the Event of Pregnancy
Subjects will be instructed to notify the investigator if they  become pregnant at any  time during 
the study , or if they  become pregnant within [ADDRESS_238157] dose of SOF/ VEL or if they  
become pregnant within 6 months (7 months for partners of male subjects) of the last dose of 
RBV. Subjects who become pregna nt or who suspect that they  are pregnant must report the 
information to the investigator and discontinue study  drug immediatel y. Subjects whose partner 
has become pregnant or suspects she is pregnant within [ADDRESS_238158] dose of SOF/VEL or 
7months a fter the last dose of RBV, whichever occurs last must report the information to the 
investigator. 
Instructions for reporting pregnancy , partner pregnancy , and pregnancy  outcome are outlined in 
Section [IP_ADDRESS].